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ABSTRACT 
 
Neural stem/progenitor cells (NSPC) can differentiate into neurons and glial cells in the central 
nervous system. Interestingly, NSPC biology is being applied to the study of human brain tumours, 
since these cells share some common features with glioma cells. However, it is not known the 
developmental stage with more similarities to glioma cells, or the most susceptible to malignant 
transformation. 
We aimed to identify the stage(s) in the NSPC differentiation process towards astrocytes where 
cells acquire phenotype characteristics comparable to glioma cells. 
NSPC that were obtained from E15 mouse brain, were grew as neurospheres (NS) and induced 
to astroglial differentiation until 7 days in vitro (DIV). After the cellular characterization of NS and 
differentiating cells, tumour-related factors were evaluated and their behavior compared to the one of 
GL261 mouse glioma cells. 
Astroglial differentiation led to a decrease in progenitor cells, as expected. Multidrug resistance-
associated protein 1 expression decreased and autophagy marker increased with differentiation. The 
vascular endothelial growth factor (VEGF), matrix metalloproteinases and S100B protein increased 
until 2/3 DIV, while the 1 DIV cells showed the highest migratory potential towards the chemotactic 
VEGF or GL261-conditioned media.  
Comparison of data with glioma cells characteristics point to the first and second days of NSPC 
differentiation to astrocytes as the stages closing matching GL261 cells, and likely the most vulnerable 
to malignancy transformation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Astrocytes, Neural progenitor cells, Neural stem cells, Glioma cells, Gliomagenesis, 
Tumour-related factors 
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RESUMO 
 
As células estaminais/progenitoras neurais (CEPN) podem diferenciar em neurónios e células 
da glia no sistema nervoso central. A biologia das CEPN tem sido aplicada ao estudo dos tumoures 
cerebrais humanos, uma vez que estas células partilham algumas características com as células de 
glioma. Contudo, não é conhecido o estadio do desenvolvimento mais semelhante às células de 
glioma, ou o mais susceptível à transformação maligna.  
O nosso objectivo é identificar o(s) estadio(s), no processo de diferenciação das CEPN em 
astróctios, no(s) qual(is) as células  adquirem características fenotípicas comparadas às células de 
glioma. 
As CEPN, obtidas de cérebros de embriões de ratinho no 15º dia de gestação, foram cultivadas 
como neuroesferas e induzidas à diferenciação astroglial até 7 dias in vitro (DIV). Após a 
caracterização celular das neuroesferas e células em diferenciação, foram avaliados determinados 
factores tumorais e o seu comportamento comparativamente às células de linha celular de glioma de 
ratinho (GL261). 
A diferenciação astroglial levou ao decréscimo das células progenitoras, como esperado. A 
expressão da proteína associada à resistência a multidrogas decresceu, enquanto a autofagia 
aumentou ao longo da diferenciação. O factor de crescimento endotelial vascular (VEGF), 
metaloproteinases e a proteína S100B revelaram um aumento da expressão até 2/3 DIV. Ainda, o 
fenótipo correspondente a 1 DIV em condições de diferenciação foi o que apresentou maior potencial 
migratório para o VEGF ou para o meio proveniente das células de glioma.  
A comparação dos dados obtidos para os vários factores, levou-nos a sugerir o primeiro e 
segundo dias das CEPN em condições de diferenciação em astrócitos, como os estadios mais 
próximos das células de glioma, e por consequente, mais vulneráveis a transformação maligna. 
 
 
 
 
 
 
 
 
Palavras-chave: Astrócitos, Células estaminais neurais, Células progenitoras neurais, Células de 
glioma, Fatores tumourigénicos, Gliomagénese. 
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1. Neural Stem Cells 
 
The term “stem cell” was originally proposed by Heackel in 1868 as cited by Breunig et al. 
(2011). Stem cells are a class of undifferentiated cells with the ability to differentiate into specialized 
cell types. They can also generate new stem cells by self-renewal and can be classified according to 
their sources: embryonic stem cells (that arise from the blastocyst phase of embryonic development) 
and adult stem cells (that arise from adult tissue). Stem cells can give rise to several cell types with 
more limited self-renewal and proliferation ability, including neural stem cells (NSC). 
NSC only became popular in the early 1990s (Breunig et al., 2011) and are described as a brain 
population with the ability of self-renewal, capable to maintain a pool of neural stem-like cells 
(extensive proliferative potential). These cells can also differentiate into more restricted precursor 
cells, designated by neural precursor cells (NPC) that are able to produce the three major cell types 
that compose the central nervous system (CNS): neurons, astrocytes and oligodendrocytes (Gage, 
2000; Siebzehnrubl et al., 2011; Temple, 2001) (Fig. I.1). 
NSC present a promising therapeutic tool for brain disorders, as they might be used to replace 
virtually any type of neuron lost from neurodegenerative disords such as Parkinson’s disease (PD), 
Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS) (Breunig et al., 2011; Parish et al., 
2008). Interestingly, NSC show tropism for brain tumours, namely gliomas and thus, they can be used 
as carriers for anti-tumourigenic drugs (Aboody et al., 2000; Noble, 2000). However, if in one hand 
NSC may have a therapeutic potential, on the other hand it is suggested that these cells might 
generate brain tumours, due to their high proliferative potential. Hence, it is very important to 
understand the mechanisms by which NSC generate the diversity of their resulting progeny (Breunig 
et al., 2011; Vescovi et al., 2006). 
 
 
Fig. I.1 – Classical view of neural stem cells hierarchy. The normal neural stem cell production of progenitor 
cells, which subsequently generates the three differentiated cell types of the central nervous system: neurons, 
oligodendrocytes and astrocytes (trilineage potential). Along the differentiation process, the proliferative potential 
decrease, while the number of differentiated cells increase. 
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1.1. NSC in central nervous system development 
 
The CNS of mammals is a highly complex structure made up of a huge number of neurons, glial 
cells and synapses, all linked by extremely heterogeneous anatomical and functional relationships. 
This complex and heterogeneous cellular population derives from NSC or primary progenitors 
(Bonfanti and Peretto, 2007; Merkle and Alvarez-Buylla, 2006). Very early in the mammalian 
development, the CNS begins with the development of the neuroectoderm, which forms the neural 
plate [at embryonic day 7.5 (E7.5) in mice] and then folds, giving rise to the neural tube (at E8.5 in 
mice) (Conti and Cattaneo, 2010; Merkle and Alvarez-Buylla, 2006; Temple, 2001). Within this 
primitive neural structure, a complex and heterogeneous population of NSC and primary progenitors 
can be found, the neuroepithelial progenitor cells (NEP). NEP are radially elongated and contact with 
both the apical (ventricular) and basal (pial) surfaces of the embryonic brain (Merkle and Alvarez-
Buylla, 2006) expressing neural precursor markers such as Sox1 [SRY (sex determining region Y)-box 
1] and Nestin, due to their “stemness” properties (Conti and Cattaneo, 2010). During the development 
course, these cells undergo both symmetric and asymmetric types of division. On the first stage of 
neural development, NEP undergo symmetrical divisions to expand the neural stem cell pool (self-
renewal and proliferative potential), while in the second stage, they initiate asymmetrical division to 
generate a stem cell (that remains in the ventricular zone - VZ) and a daughter cell, that migrates 
radially outward to its final position in the brain (intermediate progenitor) (Farkas and Huttner, 2008; 
Merkle and Alvarez-Buylla, 2006).  
In a later stage, NEP also originate the radial glial cells (RGC) (around E9.5 in mice) 
(Bentivoglio and Mazzarello, 1999; Bonfanti and Peretto, 2007; Conti and Cattaneo, 2010) which are 
the principal primary progenitors of the mammalian embryonic forebrain (and early postnatal brain). 
Similarly to NEP, RGC divide in the VZ and maintain contact with the pial surface via a radially 
projecting basal process. Thus, it is thought that NEP transform directly into RGC, which are the main 
cell type in the developing brain. They are considered an important transient population once RGC  
function both as  neural progenitors and a scaffold for migrating immature neurons (Conti and 
Cattaneo, 2010). RGC express glial/astroglial markers as the glutamate aspartate transporter 
(GLAST), the glial fibrillary acidic protein (GFAP) and the brain lipid binding protein (BLBP) (Farkas 
and Huttner, 2008; Merkle and Alvarez-Buylla, 2006) and have astroglial cells anatomical-like 
features, such as endfeet on blood vessels, intermediate filaments, and glycogen granules (Merkle 
and Alvarez-Buylla, 2006). RGC can undergo symmetrical proliferative or asymmetrical neurogenic 
divisions to generate neurons (the functional unit of the nervous system), as well astrocytes and 
oligodendrocytes. These cells provide a critical support role for optimal neuronal functioning and 
survival but its differentiation potential is less broad than that of NEP (Merkle and Alvarez-Buylla, 
2006; Zhao et al., 2008). Hence, NEP and RGC comprise the first group of stem and progenitor cells 
(apical progenitors - AP) of the CNS. It is still important to refer that, in mammalian, RGC disappear 
from the brain soon after birth, giving place to a second group composed by those neural progenitors 
that undergo mitosis in the basal VZ and subventricular zone (SVZ) (basal progenitors – BP) (Bonfanti 
and Peretto, 2007; Farkas and Huttner, 2008; Merkle and Alvarez-Buylla, 2006) (Fig. I.2). 
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The SVZ, a region just above the ventricular zone (VZ), remains the stem character in the adult 
brain. Particularly, once RGC and SVZ astrocytes share many properties, it is though that both belong 
to the same lineage. Moreover, RGC of the neonatal lateral ventricular wall occupy the same region as 
the astrocytic stem cells of the adult SVZ, and they act as multipotent NSC either in vitro or in vivo. 
SVZ cells also retain a radial process and express GFAP, suggesting that RG cells may directly 
transform into SVZ astrocytes, in adult brain. In summary, current evidences suggest that NSC 
gradually transform from NEP to RGC and from these to astrocytes-like cells (Merkle and Alvarez-
Buylla, 2006).  
 
 
Fig. I.2 – Gradual transformation of radial glial cells into astrocytes-like cells, from the embryonic period 
to adulthood. Fate of radial glial (RG) cells from development (left) to adulthood (right). Different degrees of 
yellow indicate progressive maturation from RG to subventricular zone (SVZ) astrocyte-like cells, also called 
neurogenic SVZ astrocytes. In the embryo, RG cells behave as multipotent stem cells. In brain parenchyma they 
transform into SVZ astrocytes through a transient unipolar form which has lost contact with both pia mater and 
ventricular surface (in grey: ependyma). The SVZ is composed by type B cells – SVZ astrocytes stem cells 
(yellow), type C cells – transient-amplifying cells (green) and type A cells - neuroblasts (red) , such as described 
in the next section. Hence, it is thought that RG cells (in the embryo) disappear and originate SVZ astrocytes (in 
the adult).  Adapted from Bonfanti and Peretto (2007). 
 
1.2. NSC in the adult brain niches  
 
Neurogenesis in the adult mammalian CNS was first described in the 1960s (Siebzehnrubl et 
al., 2011; Till and Mc, 1961). Adult neurogenesis is maintained by NSC that persist in the adult 
mammalian brain and undergo self-renewal and have multipotency capacity generating neurons and 
macroglia (astrocytes and oligodendrocytes). Interestingly, it is thought that this adult neurogenesis 
might be related with malignant processes giving rise to adult brain tumours (Riquelme et al., 2008). 
Two germinal regions are found in the adult mammalian brain: the SVZ of the forebrain lateral 
ventricle (Fig. I.3 A) and the subgranular zone (SGZ) of the hippocampal dentate gyrus (Fig. I.3 D) 
(Doetsch, 2003; Riquelme et al., 2008; Siebzehnrubl et al., 2011). These two zones are known as 
neurogenic niches for adult stem cells because their microenvironment regulate and support self-
renewal, activation and differentiation (features of stem-like cells) (Doetsch, 2003; Riquelme et al., 
2008). Also, they have several architectural elements that contribute to the adult neurogenesis such 
as  extensive cell-cell interactions, proximity to the cerebrospinal fluid of the lateral ventricle, close 
Embryo Adult
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B
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association with blood vessels, rich extracellular matrices and specialized basal lamina (Doetsch, 
2003). Therefore, they are exposed to a variety of growth factors (Tavazoie et al., 2008). Recent data 
suggest that a major property of several stem cell niches is the intimate association with endothelial 
cells, which regulate stem cell self-renewal and differentiation (Riquelme et al., 2008).  
In the SVZ, three types of neural progenitors can be identified, type A, B and C cells (Fig. I.3 B). 
Type B cells are radial glia-like cells located in the subependymal layer. Type B cells are also 
designated as SVZ astrocytes stem cell progenitors, because they express vimentin, nestin and 
GFAP, which divide and generate transient amplifying progenitors [type C cells; GFAP
-
/ distal-less 
homeobox 2 (Dlx2)
+
] that originate neuroblasts [type A cells; GFAP
-
/ Dlx2
+
/ doublecortin (Dcx)
+
] (Fig. 
I.3 C) (Riquelme et al., 2008). Neuroblasts migrate along the rostral migratory stream to the olfactory 
bulb, where they differentiate into granule cells and interneurons (Tavazoie et al., 2008; Zhao et al., 
2008). 
The SGZ is a brain region composed by radial glia-like cells also designated by type I cells, 
which express nestin, GFAP and Sox2 [SRY (sex determining region Y) – box2]. These cells 
proliferate and generate type II cells which differentiate to granule neurons. Type I and II cells are thus 
considered the neural progenitor cells of the SGZ (Siebzehnrubl et al., 2011; Zhao et al., 2008) (Fig. 
I.3 E/F). 
In summary, adult NSC are not a population of fully undifferentiated cells; instead, they are a 
subset of cells that exhibit common features with differentiated astrocytes, such as the expression of 
GFAP but, concomitantly, they also exhibit certain RGC properties. Adult NSC are present specifically 
in the SVZ and SGZ brain regions (Doetsch, 2003; Duan et al., 2008). Following the evolutionary 
process during brain embryo development, such as the one described above, RGC are the in vivo 
primary precursors of neurons and glia, and postnatally, radial glia transition into astrocytes persists 
through type B cells (SVZ) and type I cells (SGZ) niches (Merkle et al., 2007; Riquelme et al., 2008). 
In addition to their role as stem cells, within adult neurogenic niches, these astrocyte-like cells work as 
sensors and regulators of the microenvironment. They envelop and contact all cell types and 
structures in the niches, including blood vessels and the basal lamina, allowing them to integrate 
diverse signals from many sources. Moreover, these cells are commonly associated via gap junctions 
and they have the ability to form a syncytium, which may allow them to propagate signals locally or 
throughout the entire niche, controlling activation and differentiation of stem cells (Riquelme et al., 
2008). 
To understand the generation of neurons from cells with astrocytic properties, it is necessary to 
refer some signalling pathways. SVZ astrocytes are adjacent to the ependymal cell layer expressing 
the protein Noggin that may promote SVZ neurogenesis by antagonizing signalling of the bone 
morphogenetic proteins (BMP). In SGZ neurogenesis, hippocampal astrocytes promote the 
differentiation of adult hippocampal progenitor cells into immature neurons. Lie and al. (2005), proved 
that the blockade of the Wnt signalling pathway inhibit the neurogenic activity of astrocytes in vitro and 
SGZ neurogenesis in vivo, suggesting that hippocampal astrocytes may act through Wnt signalling 
(Lie et al., 2005; Zhao et al., 2008). 
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Fig. I.3 – The adult niches, cell types and stem cell lineage. A) Frontal schematic representation of the adult 
mouse brain showing the location of the subventricular zone (SVZ). B) Schematic representation showing the cell 
types and their organization in the SVZ. Ependymal cells (blue dark) line the lateral ventricle. Groups of 
neuroblasts (red) travel through tunnels formed by the processes of SVZ astrocytes (salmon). Focal clusters of 
rapidly dividing Type C cells (green light) are scattered along the network of chains of neuroblasts. SVZ 
astrocytes occasionally extend a process to contact the lateral ventricle. C) SVZ astrocytes (Type B cell) act as 
stem cells in this region and divide to generate transit-amplifying (Type C cell), which in turn divide to generate 
the neuroblasts (Type A cell) that migrate to the olfactory bulb. D) Frontal schematic representation showing the 
location of the SGZ in the hippocampus. The SGZ lies between the granular cell layer and the hilus. E) Schematic 
representation showing the cell types and their organization in the SGZ. SGZ astrocytes (Type I cell, orange) are 
in close proximity to blood vessels (endothelium, grey). Endothelial cells are likely an important source of signals 
for neurogenesis. F) SGZ astrocytes divide to generate intermediate precursors (Type II cell, blue), which 
generate granule neurons (green dark). Dcx (doublecortin), Dlx2 (distal-less homeobox 2), GFAP (glial fibrillary 
acidic protein). Adapted from Doetsch (2003); Riquelme et al. (2008); Vescovi et al. (2006). 
 
1.3. Therapeutic potential of NSC 
 
The physiological loss of tissue homeostasis during life gives rise to a progressive and 
extensive decline in the physical and cognitive performance. This loss could be aggravated by 
pathological factors triggering the development of disorders such as PD, AD and ALS. Apart from 
neurodegenerative disorders, the brain tumours are another serious pathology that dramatically 
affects the quality of life and life expectancy in patients (Artegiani and Calegari, 2012; Goldman and 
Windrem, 2006). 
For many CNS diseases, particularly in cancer, treatment options are very limited. Surgical 
intervention is restricted by the local limited accessibility, as well as by the high risk of disturbing vital 
normal brain functions. Also, the use of systemic chemotherapeutics might not be effective due to the 
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largely impermeable blood-brain barrier (BBB) (Joo et al., 2012). Similarly to the chemotherapy, 
radiation therapy is a common modality for the treatment of various brain tumours; however it is clear 
that these therapeutic regimens may themselves produce injury, being often associated with 
significant cognitive impairment (Joo et al., 2012; Noble, 2000). Hence, stem cell-based therapies 
have been lately proposed and might represent a plausible alternative strategy in several of these and 
other disorders (Bonnamain et al., 2012; Pluchino et al., 2005). NSC display a strong tropism for 
tissue lesions and seem to migrate towards critical sites to release molecules aimed at preventing cell 
death and facilitating regeneration of targeted cell populations. Moreover, this migratory capacity 
makes these cells of particular interest as therapeutic delivery vehicles directly into the lessoned area 
using genetically engineered stem cells (Bonnamain et al., 2012; Noble, 2000). Thus, NSC therapeutic 
potential can be addressed in two different ways - through endogenous NSC or, in the other hand, 
through the transplantation of these cells, depending on the type of brain injury (Pluchino et al., 2005). 
Endogenous adult NSC, existing mainly in neurogenic niches (namely SVZ and SGZ, as described in 
the previous section) may endure neurogenesis and gliogenesis in response to several different 
injuries such as those occurring during inflammatory, ischemic, or traumatic events, acting as part of 
an “intrinsic” brain self-repair process during adulthood (Pluchino et al., 2005; Taupin, 2006). It is 
believed that these insults may trigger a cascade of cellular and molecular signals, mediated by the 
release of soluble mediators (cytokines, chemokines, metalloproteases, adhesion molecules, etc) 
capable of supporting neurogenesis and gliogenesis that, in turn, favours brain regeneration (Chang et 
al., 2012; Pluchino et al., 2005). Nevertheless, the intrinsic signals are not sufficient to promote 
proliferation and differentiation of NSC. Therefore, regeneration could be triggered by the stimulation 
of endogenous repair mechanisms at sites of degeneration leading NSC to secrete a plethora of 
trophic factors able to protect and prevent neural cell damage, and to re-establish the functional 
interactions between neural and glial cells (De Feo et al., 2012; Taupin, 2006). Studies revealed that 
in the SVZ, newly generated neuronal cells migrate partially through the rostro-migratory stream to the 
sites of nerve cell degeneration (Arvidsson et al., 2002). For instance, recent studies report that 
selective-serotonin reuptake inhibitors, such as fluoxetine, stimulate proliferation of NSC and increase 
the number of cells with neuronal features. It was shown that fluoxetine promotes both proliferation 
and neuronal differentiation of NSC and exerts protective effects in NSC, suggesting its therapeutic 
usage in several neurodegenerative diseases, such as AD and PD, considering its actions on NSC 
(Chang et al., 2012). Despite the generation of new neuronal cells at the sites of degeneration, this is 
insufficient to promote functional recovery after neurological injuries. This failure results from the low 
number of new neurons generated, or even because they are non-functional (Joo et al., 2012; Taupin, 
2006).  
The transplantation of NSC appears as another type of cellular therapy based mainly on the 
ability of transplanted NPC to migrate and adapt their behaviour and fate to the CNS 
microenvironment, and to promote neuroprotection via different and articulated strategies 
encompassing not only cell replacement, but also the so-called “bystander” effect (a mode of action 
named “therapeutic plasticity”) (Colleoni and Torrente, 2008; De Feo et al., 2012; Pluchino et al., 
2005). Anatomic and pathologic characteristics of CNS disorders such as PD, spinal cord injury, 
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Huntington´s disease or stroke, suggest that intracerebral transplantation of these cells directly at the 
site of the lesion would be the more appropriated strategy to facilitate tissue regeneration (Bonnamain 
et al., 2012). Neural stem/progenitor cells (NSPC) can spontaneously differentiate in vivo under the 
influence of the microenvironment, in cells with the desired phenotypes. In fact, it was recently shown 
that undifferentiated human NSPC have the capability to survive and differentiate into neurons and 
glial cells after xenotransplantation in the rat spinal cord (Mothe et al., 2011). On the other hand, this 
therapeutic strategy has also been considered for tumour treatment because the behaviour of NSC 
although capable of being influenced by the tumour signals, have the ability to target the primary 
tumour mass, tumour outgrowths and distant tumour pockets (Colleoni and Torrente, 2008; De Feo et 
al., 2012). The transplanted NSC might carry some genes/factors of interest, such as genes encoding 
proteins that induce differentiation of neoplastic cells and/or their signal-transduction mediators, cell 
cycle modulators, apoptosis-promoting agents, anti-angiogenesis factors, immune-enhancing agents 
and oncolytic factors (Colleoni and Torrente, 2008). The signals and factors that might influence the 
tumour tropism of NSC and their interaction within the tumour environment are currently under 
investigation. However, it is speculated that soluble factors (overexpressed by tumour cells) may be 
an important signal for the long-range attraction of NSC from distant sites. Recent studies indicate that 
tumour-upregulated vascular endothelial growth factor (VEGF) and stromal cell-derived factor-1 (SDF-
1) act as soluble chemotactic factors inducing tropism of NSC (mainly to glioma). The presence of 
these chemoattractant factors may allow NSC to communicate with each other and facilitate the 
observed migration (Colleoni and Torrente, 2008; Joo et al., 2012). Particularly in brain tumours, over 
the last years, studies about the potential use of NSC as a therapeutic tool for glioblastoma have been 
reported. For instance, in 2000, Benedetti et al. reported that NSC genetically modified to produce 
interleukin-4 (IL-4) that could promote tumour regression and prolonged survival in mice injected 
intracranially with the GL261 mouse glioma cell line (Benedetti et al., 2000). Later, Ehtesham et al. 
(2002) demonstrate that the inoculation of NSC transduced with tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL) (a member of the tumour necrosis factor protein super family) into 
human glioma drove to potent induction of tumour cell apoptosis and consequently to a highly 
significant decrease in tumour volume. 
 Nowadays, due to the limited delivery of drugs to brain tumours (hindered primarily by BBB), 
drug delivery nanosystems are being studied, such as nanoparticles (NP), which include nanospheres 
and nanocapsules, micelles, dendrimers, nanocrystals, and nanogolds (Roger et al., 2011). The 
therapeutic agents (such as anticancer drugs), can be encapsulated into the NP (Lopes et al., 2011) 
and then carried by them (Garcion et al., 2006; Huynh et al., 2009; Roger et al., 2011). Thus, NP can 
protect therapeutic agents from chemical or enzymatic degradation and allow their sustained and 
controlled release (Roger et al., 2011), being these drug-loaded NP administered by systemic or direct 
delivery to the CNS. Thus, due to the special tropism of NSC, NP and stem cells to glioma cells, these 
are promising tools to treat brain tumours (Ferreira et al., 2008). NP have been shown to enter inside 
the target cells via passive transporter (Banerji and Hayes, 2007) or active endocytosis (Lorenz et al., 
2006; Rejman et al., 2004). Once inside the cells, NP are usually transported to the endo-lysosomal 
system, where they are destroyed, and to release the pharmacotherapeutic agents in the cytoplasm. 
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Inside NSC, NP can be administered directly into the brain via a intratumoural or contralateral injection 
into the tumour mass (Fig. I.4) (Roger et al., 2011). 
 
 
 
Fig. I.4 – Schematic representation of nanoparticles delivery by neural stem cells inside a brain tumour. 
A) Incorporation of nanoparticles (NP) containing anticancer drugs into neural stem cells (NSC). B) Delivery 
strategy: 1. Intratumoural injection of NSC loaded with NP into the tumour mass. 2. Migration of NSC loaded with 
NP. 3. NSC distribution at the border between normal brain parenchyma and the tumour mass. 4. Release of the 
therapeutic agent. Adapted from Roger et al. (2011).  
 
The stimulation of endogenous neural progenitor and stem cells, and the transplantation of 
adult-derived neural progenitor and stem cells may represent valid strategies for the treatment of a 
broad range of CNS diseases and injuries. However, their clinical application is limited by both ethical 
and logistical problems such as their isolation and their immunological compatibility in allogenic 
transplantation (Colleoni and Torrente, 2008; Taupin, 2006). 
 
1.4. In vitro culture of NSC: the neurosphere assay  
 
NSC sources are located in inaccessible areas within the brain, thus severely limiting their 
clinical utility. Hence, it is highly desirable and urgent to find an alternate source of neural cells (Sun et 
al., 2011; Suzuki et al., 2004). Working on an attempt to find a method of expanding NSPC, several 
groups contributed to the discovery of two culture systems for the maintenance and expansion of 
NSC: neurospheres (NS, in suspension) and adhesive substrate-bound (adherent) cultures. Both 
systems are good culture methods; however, although the adherent culture is richer in NSC and grow 
significantly faster than NS, it could only maintain robust growth during 6-7 passages, while NS could 
be maintained for more than 10 passages (Sun et al., 2011).  
 “NS”, the culture system used in the present thesis, was performed for the first time by 
Reynolds and Weiss (1992). They have demonstrated that cells from embryonic or adult nervous 
system can be cultivated and propagated in vitro as NS from single NSC, suggesting their potency for 
self-renewal (Zhao et al., 2008). NS agglomerate and form spherical clusters and can be expanded in 
long term suspension cultures, in the presence of growth factors (Bez et al., 2003; Breier et al., 2010). 
These cellular structures represent three dimensional heterogeneous clusters of proliferating cells, 
B)
NSCNP
In vitro incorporation in cells
A)
1
2
4
3
Tumour mass
I. INTRODUCTION 
11 
 
including stem cells, committed progenitors, and differentiated cells such as neurons, astrocytes and 
oligodendrocytes (Bonnamain et al., 2012; Breier et al., 2010; Garbossa et al., 2012). 
The morphological and functional heterogeneity of these free-floating structures is observed and 
evaluated through several factors as size, apoptosis, phagocytosis, proliferation/self-renewal, 
differentiation and migration. Spheres of different sizes could be generated from cells plated at the 
same time and under identical culture conditions, resulting in larger NS (with a dark core) and/or 
smaller ones (more translucent) (Bez et al., 2003). The size of NS influences their cell activity in that 
the highest cell activity (i.e., mitosis, protein synthesis) occurs at the periphery of the agglomerates 
more accessible to nutrients and oxygen, while necrosis, and low or absent mitotic and transcriptional 
activity, are typical of the inner layers where nutritional exchanges are more difficult. Moreover, results 
of propidium iodide (PI)/Hoechst staining (to detect cellular death), showed some PI
+
 cells on the core 
of the big floating-free structures (Fig. I.5A) (Bez et al., 2003; Sun et al., 2011).  
NSC derived from NS are not synchronized and can be in any phase of the cell cycle. Besides 
nestin (Fig. I.5C1) and Sox2 (Fig. I.5D1), markers of NPC, NS also express MAP2 (microtubule-
associated protein 2, mature neuron marker) and GFAP, showing that the culture is also composed of 
mature neural populations (Sun et al., 2011). As expected, nestin
+
 undifferentiated cells are located in 
the periphery of the sphere, while differentiated neuronal (βIII-tubulin+) and glial (GFAP+) cells 
(Fig.I.5B) reside in the center, probably due to a growth factor gradient from the outside to the inside 
of the sphere (Breier et al., 2010). Cell proliferation might be the most important feature of NS, and 
both the epidermal and fibroblast growth factors (EGF and FGF, respectively) have a crucial role in the 
NSPCs cell cycling maintenance. The self-renewal and proliferation can be shown and quantified by 
the presence of immature cells (nestin+) and cycling cells [5-Bromo-2’-Deoxyiridine (BrdU+)] in the 
outer layer of the cluster. This double immnunofluorescence staining shows that BrdU
+
 cells are also 
nestin
+
 cells (Fig. I.5E4) (Sun et al., 2011). In the same way that growth factors maintain the 
proliferative characteristics, their withdrawal drive cells to stop proliferating and start differentiating and 
expressing neurotrophins. This, will cause a 50% decrease in BrdU labelling and nestin expression,  
and  an increase in the number of GFAP
+
 and β-tubulin III
+
 cells (Schwindt et al., 2009). With growth 
factors withdrawal, neural progenitor cells migrate radially out of the sphere onto a given extracellular 
matrix (ECM), and thereby differentiate into cells expressing neural and glial markers which form the 
migration area, while the zone pattern inside the sphere disappears. After some time of differentiation, 
βIII-tubulin
+
 cells are found at the edge of the sphere while nestin
+
 and GFAP
+
 cells are 
heterogeneously distributed throughout the sphere (Breier et al., 2010; Schwindt et al., 2009). 
Additionally, the dissociation of NS also favours differentiation of dissociated cells into O4
+
 
oligodendrocytes, GFAP
+
 astrocytes or βIII-tubulin (TuJ1)
+ 
 neurons (Bez et al., 2003; Sun et al., 
2011). 
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Fig. I.5 – Principal feactures and phenotypes of neurospheres. A) Dead cells (red) in the core of the 
neurosphere (NS) are labeled with propidium iodide (PI) (red) and nuclei are counterstained with Hoechst 33342 
(blue). Scale bar represents 30 µm. B) NS with a central core of glial fibrillary acidic protein (GFAP) positive glia 
(green) surrounded by nestin (red) positive neural stem cells at the sphere edge. Scale bar represents 50 µm. C1) 
and D1) NS contain nestin-positive (red) and Sox2-positive [SRY (sex determining region Y)-box 2 (green)] cells, 
respectively. C2) and D2) Nuclei were stained with DAPI (4',6-diamidino-2-phenylindole, blue). C3) and D3) 
merge of images C1+C2 and D1+D2, respectively. Scale bar represents 100 µm in the series C and 20 µm in the 
series D. E1-4) Staining for nuclei (DAPI), proliferation (BrdU, red) and nestin (green). Scale bar represents 30 
µm.  Figure A and E are from Sun et al. (2011), B is from Lu et al. (2010), and C and D from Wang et al. (2007). 
 
As referred above, the characteristic migration of these cluster cells is easily assessed because 
upon growth factors withdrawal, NPC start leaving the sphere in a 90
o
 angle and their travel distance 
over time can be measured through a phase contrast microscope. The process of migration is 
regulated by intracellular, as well as extracellular stimuli. The migration of human NPC out of the 
neurosphere is controlled by the mitogen MAPK (mitogen activated protein kinase) ERK1/2 
(Extracellular signal-regulated protein kinases 1 and 2) –dependent and –independent pathways. 
Moreover, human neural progenitor cell migration is preserved on collagen, fibronectin and poly-L 
lysine matrices, indicating a crucial role of the ECM in neural migration not only in vivo, but also in vitro 
(Breier et al., 2010). 
Overall, the importance of having a reliable model of NSPC is related to the fact that these cells 
can serve as a valuable source of cell type-specific somatic precursors for neural transplantation, thus 
C1 C2A
B
D1
C2
C3
D2
D3
E1 E2 E3 E4
I. INTRODUCTION 
13 
 
offering a potential starting point for therapy of neurodegenerative diseases. In addition, this model 
can also be a useful tool for testing neurotoxic substances for their abilities to interfere with basic 
process of brain development, such as proliferation, migration, differentiation and apoptosis, a 
procedure that was called by developmental neurotoxicity testing (Breier et al., 2010).  
 
 
2. Neural stem cells, tumour stem cells and brain tumours: dangerous 
relationships? 
 
Brain tumours are a wide group of abnormal masses of tissue as a result of uncoordinated 
proliferation of cells (neoplasms) with a high incidence in children and adults with the poorest outcome 
among the human cancers. In adults, their incidence is relatively high, especially in elderly people; in 
children, brain tumours are the second commonest type of cancer (17% of all childhood’s cancer) and 
cause 25% of cancer deaths. Until now, only small changes have been registered in these numbers 
and they continue to be associated with very high morbidity and mortality (Dirks, 2008; Sutter et al., 
2007).  
There are different types of brain tumours with neuroepithelial origin, that have been classified 
based on the histological resemblance of tumour cells to cells present in the adult brain, and thus 
focusing in the cell types that compose the tumour mass (Sanai et al., 2005) (Fig. I.6). Although this 
classical classification is used by most authors, more recently, and according to the 2007 report 
published by the World Health Organization (WHO), brain tumours have been classified not only 
based on a single cell type but there were included also mixed type of tumours, such as the mixed 
neuronal-glial (Louis et al., 2007; Sutter et al., 2007; Vescovi et al., 2006). 
Brain tumours are a heterogenous group of malignancies that originate and reside within the 
brain, contrary to metastatic brain tumours that originate from a primary cancer outside the CNS and 
spread to the brain (Germano et al., 2010). They are organized as a cellular and functional hierarchy 
based on a subpopulation of brain tumour cells that have, surprisingly, stem cell properties. Both 
tumour and NSC are morphologically simple, express many of the same specific genes and proteins, 
can differentiate into cells of various shapes and sizes, and have the ability for extensive growth 
(Wechsler-Reya and Scott, 2001). These shared features, together with the ability of this tumour cell 
population to form NS and to be repeatedly passaged/proliferated (self-renewal capacity), are used as 
indicators of stem cell properties of the tumour cells, giving them the designation of brain cancer stem 
cells (CSC). However, although CSC and NSC shared a lot of characteristics, there are some 
differences between them, particularly in what concerns to cell proliferation. In fact, while NSC 
possess a tight control of the asymmetric cell division and can maintain a relative balance between 
self-renewal and differentiation, CSC are characterized by uncontrolled proliferation or self-renewal. 
Hence, it is thought that if NSC acquire genetic mutations that impair asymmetric divisions, they might 
turn into CSC and induce tumourigenesis (Dirks, 2008; Vescovi et al., 2006; Yao et al., 2009). 
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Current treatment strategies for brain tumours include surgery, radiotherapy, and 
chemotherapy. Nevertheless, these clinical interventions modestly improve patient survival. In 
addition, treated patients often have intellectual impairment related to chemotherapy and radiotherapy. 
Moreover, even brain tumours classified as benign can be lethal due to their location in surgically 
inaccessible areas (Yao et al., 2009; Dirks, 2008). The core of treatment failure derives from the poor 
understanding of the cellular and molecular mechanisms regulating tumour growth. Thus, it is very 
important to understand how cells in the diverse tumour populations initiate and maintain growth, and 
which are the molecular mechanisms involved and the brain cells that suffer malignancy 
transformation and give rise to brain tumour (Dirks, 2008). Hence, it is necessary to analyse 
asymmetric and/or symmetric division directly on tumour stem cells and to compare the signalling 
pathways involved in NSC with those in CSC proliferation (Yao et al., 2009). 
 
 
Fig. I.6 – Cell types and associated tumours of the central nervous system. Brain tumours have been mostly 
classified based on the histological resemblance of tumour cells to central nervous system (CNS) cells, such as 
astrocytes, neurons, oligodendrocytes and ependymal cells. Adapted from Sanai et al. (2005). 
 
2.1. Gliomas – an overview 
 
Gliomas are the most common type of brain tumours, accounting for more than 70%. Gliomas 
consist of a heterogenous mixture of several glial phenotypes, composed by immature cell types, 
poorly differentiated neoplastic astrocytes and mature cells. These tumours can either develop by 
dedifferentiation from a low grade tumour (“secondary glioma”) or can arise “de novo” (“primary 
glioma”). Differences in clinical and molecular features of the two types of glioma point to a distinct 
pathogenesis (Park and Rich, 2009; Siebzehnrubl et al., 2011). Some controversy still exists in turn of 
the origin of these brain tumours, once some authors refer to NSC as the cells that undergo molecular 
and cellular transformation generating the tumoural growth, while others think that glioma arises from 
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dedifferentiation of mature glia (Sanai et al., 2005; Vescovi et al., 2006). However, if the last 
hypothesis has been increasingly discarded, the glioma origin from NSC is the most accepted and the 
one intensively researched reason why this assumption was followed in the present thesis.      
According to their histological features, there are three main types of the most common gliomas: 
astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas (Siebzehnrubl et al., 2011). 
According to the WHO, gliomas are organized into four different grades based on histological 
properties of cellular composition, nuclear morphology and atypical cell stage, mitotic activity, necrotic 
features, and microvascular proliferation (Louis et al., 2007; Ohgaki and Kleihues, 2005). A higher 
histological grade corresponds to a less differentiated phenotype and to an increasing malignancy 
(Park and Rich, 2009). Regarding astrocytomas, the main focus of the present work, they can be 
classified in low grade/WHO Grades I and II or high-grade or malignant/WHO Grades III and IV (Louis 
et al., 2007; Siebzehnrubl et al., 2011) (Table I.1.). 
 
Table I. 1 – Astrocytoma grades. Astrocytomas can be divided in four groups based on their malignant grade 
and general tumour characteristics, in accordance to World Health Organization.  
 
 
The latter two tumour subtypes are considered the most malignant gliomas and are associated 
with a very poor prognosis. Particularly, glioblastoma multiforme (GBM) accounts for 50% of primary 
brain tumours and only 5% of patients have a 5 years survival rate, meaning that the average survival 
rate is approximately only 14 to 15 months (Ohgaki and Kleihues, 2005; Stupp et al., 2005; Sutter et 
al., 2007). The peak of the onset of GBM is between 50 and 55 years, which makes it an age-related 
disease, and male are slightly more prone to this pathology than female individuals. Moreover, the 
black people undergo an incidence 2-3 times higher than white people (DeAngelis, 2001; Stupp et al., 
2005). 
Although gliomas are a relatively rare form of cancer, they account for a disproportionately high 
morbidity and mortality because their location in the brain is generally problematic to surgery and other 
therapies. Their treatment is a daunting challenge to clinicians due mainly to the lack of effective 
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therapeutic options. Gliomas rarely metastasize outside of the brain, but instead, infiltrate extensively 
into surrounding normal brain tissue. Thus, although the surgery is not curative it can establish the 
diagnosis. It is taken as the first choice because the resection of the tumour is important to decrease 
the pressure it exerts and is usually followed by focal external beam radiation (Germano et al., 2010; 
Park and Rich, 2009). Subsequently, radiation therapy and chemotherapy increase survival, but 
disease recurrence is virtually inevitable (Park and Rich, 2009). Besides these difficulties it is 
observed that the average survival after surgical resection alone is six months with only 7.5% of 
patients surviving two years post-operatively. Adding radiation therapy, this average survival prolongs 
to nine months, while systemic chemotherapy provides minimal survival benefits (Siebzehnrubl et al., 
2011).  
The latest researches have attempted the use of systemic chemotherapy with alkylating agents 
such as temozolomide (TMZ). Thus, since 2005, the care standard for newly diagnosed patients with 
GBM includes resection, fractionated radiation concurrent with TMZ chemotherapy, followed by TMZ 
alone (DeAngelis, 2001). This association between surgery, radiation and chemotherapy is not able to 
avoid that the recurrence in high-grade gliomas will occur in more than 90% of cases, frequently within 
2 cm of the original site, but 10 to 20% of the cases may develop new lesions at distant sites 
(Germano et al., 2010). However, it showed to increase the overall survival by 2.5 months, the 
progression-free survival by two months and the two-year survival by 16% (DeAngelis, 2001). Despite 
the important effort that has been made to find therapeutic agents and the development of GMB 
models representing the features of human malignancy, the poor identification of the malignant tumour 
initiating cells has limited the development of more effective therapies (Siebzehnrubl et al., 2011). 
Overall, the lack of knowledge about the relationship between the normal cell and the 
tumourigenic cellular transformation, as well as the poor information about the characteristic tumour 
heterogeneity, have delayed the identification of new molecular targets and the development of novel 
target therapeutic processes to apply in GBM treatment. Hence, it is necessary a better understanding 
of the mechanisms involved in the tumour origin and progression, to allow the discovery of new and 
more effective therapies. 
 
2.2. Cancer stem cell hypothesis 
 
 Tumours are currently viewed as a disruption of the cellular organization mechanisms resulting 
from accumulation of genetic and epigenetic events at the germ line and somatic levels. The cell of 
origin of cancer has been a strongly debated topic throughout the history of cancer research, and over 
the last few years the idea that cancer is a disease driven by CSC has emerged (Bapat, 2007; 
Houghton et al., 2007), as referred on the beginning of this chapter.  
Although the concept of CSC has been originally proposed in 1990s, the first evidence of the 
presence of cells with stem-like characteristics in human brain tumours was only reported later by 
Ignatova et al. (2002) who isolated clonogenic neurosphere-forming precursors from post-surgery 
specimens of human GBM. These stem-like cells expressed both neuronal and astroglial markers, 
together with several key determinants of neural stem-cell fate (Fig. I.7). Afterwards, several groups 
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have shown the presence of these cells within brain tumours; for instance, two different groups 
demonstrated that both GBM and medulloblastoma contain NS-forming cells that can give rise to 
neuronal and astroglial-like cells (Hemmati et al., 2003; Singh et al., 2003). 
The identification of CD133 (prominin 1) immunoreactive cells in brain tumours and their 
characterization as CSC was based on the fact that the glycosylated epitope of the CD antigen AC133 
appeared to be restricted to stem cells. These CD133+ cells in brain tumours were shown to be  highly 
tumourigenic (Germano et al., 2010) and express molecular markers associated with neural 
precursors, such as nestin, the transcription factor Sox2, the RNA binding protein Musashi, B-cell-
specific Moloney murine leukemia virus integration site 1 (Bmi-1), Notch, the transcription factor Emx2, 
paired box 6 (Pax6) and the ligand for the receptor notch 1 (Jagged1). However, when exposed to 
differentiation conditions, these cells downregulate the expression of these immature markers and 
acquire immunoreactivity for βIII-tubulin (for neurons), GFAP (for astrocytes) and platelet-derived 
growth factor receptor-α (PDGFRα)  (for oligodendrocytes) (Dirks, 2008; Germano et al., 2010; Sutter 
et al., 2007). Additionally, the CD133+ population is resistant to several chemotherapeutic agents 
(such as TMZ, carboplatin, placlitaxel and etoposide) and to radiation therapy (Germano et al., 2010; 
Yao et al., 2009). These cells by showing karyotypic and other genetic alterations are indeed 
neoplastic and not residual NSC entrapped in the tumour (Fig. I.7) (Germano et al., 2010).  
Altogether, these findings demonstrate that: a) different brain tumours are composed by 
transformed, undifferentiated neural precursors that respond to the same mitogens and activate adult 
NSC; b) tumour stem-like cells possess some of the molecular features of NSC; c) CD133, a cell-
surface protein that is a marker of normal human neural precursors, can be used for the enrichment of 
tumour stem-like cells from brain tumours; and d) tumour stem-like cells have the ability to maintain 
stem cell function and to promote tumour growth. These findings and assumptions led to the cancer 
stem cell hypothesis in GBM and in other solid tumours, such as medulloblastomas and 
ependymomas (Taylor et al., 2005).   
In the core of the relation between NSC and CSC there is a difference related to self-renewal. 
While NSC can maintain a controlled balance between self-renewal and differentiation, CSC are more 
long-lived. Indeed, these tumour-derived NS could be cultured for at least four months without relevant 
changes in their proliferative properties, whereas normal NS grown under identical conditions 
persisted no longer than one month in culture (Sutter et al., 2007). Hence, this uncontrolled 
proliferation can be in the origin of the brain tumour. So, if a normal NSC, during its life, accumulates 
enough mutations and undergoes neoplastic transformation, it would then become a CSC, forming 
and maintaining a brain tumour. Moreover, a recent work developed by Jackson and colleagues 
(2006), has shown that NSC into the SVZ express PDGFRα and the administration of exogenous 
PDGF (platelet-derived growth factor) initiates a signalling cascade that induces aberrant proliferation 
of these cells leading to formation of hyperplastic lesions, with properties like gliomas, which, however, 
regress upon PDGF withdrawal. So, this deregulation of the PDGF signalling suggests that genetic or 
epigenetic mechanisms affecting the proliferation of NSC can be an early factor in brain tumour 
formation (Sutter et al., 2007). Thus, it is hypothesized that CSC can be generated from the oncogenic 
transformation of NSC residing in the SVZ, rather than from lineage of committed progenitors (Fig. 
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I.7). In fact, there is another hypothesis for the origin of CSC that refers to the processes of 
dedifferentiation from astrocytes (Germano et al., 2010), which will not be any further discussed along 
the work. 
 
 
Fig. I.7 – Schematic representation of the relationship between neural stem cells, neural progenitor cells, 
cancer stem cells and brain tumours. Cancer stem cells (CSC) originate from neural stem cells (NSC) or 
progenitor/differentiated cells upon acquisition of genetic mutations, giving rise to brain tumours. The features of a 
brain tumour stem cell are: self-renewal, proliferation in vitro, multipotency with aberrant differentiation pattern, 
expression of stem cell markers and karyotypic or genetic alterations. Adapted from Sutter et al. (2007). 
 
Because of brain tumours complex organization, its effective treatment is a very difficult task. 
The conventional therapies that act over dividing cells, although reduce partially tumour bulk, they 
often do not prevent tumour regrowth, probably because this kind of approach is not able to destroy 
the CSC (Sutter et al., 2007). This resistance of CSC to radiation and chemotherapy has been 
attributed to the quiescent phenotype and enhanced DNA (deoxyribonucleic acid) repair in CSC, as 
well as to the expression of drug efflux pumps and anti-apoptotic proteins (Gilbert and Ross, 2009; 
Houghton et al., 2007). The work developed by some researchers, as Bao et al. (2006) have shown 
that CD133
+
 glioma cells survive to radiation and chemotherapy due to the activation of DNA damage 
response, leading to a better repair of radiation-induced DNA damage, as well as by the upregulation 
of drug resistance genes expression that make the CSC insensitive to chemotherapy (Sutter et al., 
2007). This multidrug resistance phenomenon can be mediated by several ATP-binding cassette 
(ABC) transporters, such as the protein encoded by the multidrug resistance protein (MDR), the 
multidrug resistance-associated protein (MRP), and the breast cancer resistant protein (BCRP). 
Surprisingly, some of these transporters are also expressed in many kinds of normal stem cells 
(Kondo, 2006; Sutter et al., 2007). Moreover, Ghods et al. (2007) described the upregulation of anti-
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apoptosis-related genes that may  also account for treatment resistance (Sutter et al., 2007).  
Therefore, the discovery of new targets in CSC and more directed brain tumour therapies are new and 
promising concepts considered to be necessary to improve the actual poor prognosis of these highly 
aggressive and devastating tumours. 
 
2.3. Cues for glioma origin 
 
The determination of the cellular origin of gliomas is very important to better understand this 
disease and to develop new therapeutic approaches. As described above, it is thought that gliomas 
are originated by the transformation of NSC or NPC. According to some recent works, modifications in 
the normal glial NPC differentiation can lead to the generation of abnormal cells, instead of mature 
astrocytes (or oligodendrocytes). This hypothesis for glioma origin has been explored because NSC 
and NPC, share some characteristics with gliomas, such as: high proliferation and motility, association 
with blood vessels and white-matter tracts, evidence immature antigenic phenotypes, and 
“developmental” signalling pathways activation (Sanai et al., 2005). In addition, regarding tumour 
location, many gliomas are localized in the SVZ of the adult brain, a germinal region where NSC are 
also localized (Sanai et al., 2005), suggesting that gliomas can be generated by the cells of this 
region.  
Proliferation is a very important feature of brain tumours, and in fact, the regions of the brain 
with a high degree of cellular proliferation are more sensitive to chemical or viral oncogenesis than 
areas with a low proportion of proliferating cells (Sanai et al., 2005). FGF and Notch signalling, that 
are involved in the regulation of NSC proliferation and renewal, are also involved in gliomas 
proliferation. Furthermore, epidermal growth factor receptor (EGFR) expression is up-regulated in 
primary GBM and in transiently dividing progenitors (type C cells) (Levy et al., 2008).  
Nowadays, the heterogeneity of glioma has been much studied because it has been observed 
that GBM have clonogenic NS i.e., forming cells that express both neuronal and glial markers upon 
differentiation (Ignatova et al., 2002). However, the diversity of their progeny may be limited by the 
blocked-differentiation phenomenon, because although the transformed progenitor cells divide rapidly, 
their progeny are incapable of complete differentiation. Thus, the tumour phenotype may be defined 
by the direction and differentiation stage of the transformed progenitor population. For example, 
astrocytoma can arise from glial progenitors whose progeny can differentiate only along astrocytic 
lines. Although this scenario suggests that the cell of origin for gliomas is a stem cell, it also indicates 
that the cell of origin has undergone a transformation event that limits the normal differentiation of its 
progeny (Sanai et al., 2005). This heterogeneity of cell types in tumour mass is demonstrated by the 
identification of immature phenotype markers, such as Bmi-1, Nestin, Sox2, Musashi, stage-specific 
embryonic antigen-1/CD15 (SSEA-1), and activated Notch pathways, as well as by markers of mature 
astrocytes and oligodendrocytes (Park and Rich, 2009; Levy et al., 2008). Hence, the state of 
differentiation is an important feature of the cell in the origin of gliomas because, although the 
influence of the state of differentiation depends on the oncogenes involved, the risk for malignant 
transformation of stem and progenitor cells in the CNS are at particularly also derives from their 
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activated cellular machinery (e.g., promitotic genes, telomerase activity, and antiapoptotic genes), 
which is determinant for tumour initiation, progression, or both (Park and Rich, 2009; Sanai et al., 
2005). Other oncogenes are similarly involved in this transformation. For example, the combination of 
oncogene activation (RAS) and disruption of a tumour suppressor gene (lnk4a-Arf) provides an 
adequate oncogenic stimulation for tumourigenesis of both nestin-positive NPC and differentiated 
astrocytes (Uhrbom et al., 2002). Moreover, astrocytic-specific inactivation of NF1 gene fails to 
produce gliomas, but loss of this gene function in the development of the brain leads to the 
proliferation of glial progenitors and optic glioma formation. In addition, excision of two tumour 
suppressor genes, p53 and NF1 in mice results in the formation of astrocytomas only in the SVZ, a 
region made up by multipotent NSC (Park and Rich, 2009). Still, PTEN (phosphatase and tensin 
homolog), a tumour suppressor gene with an important function in the control of NSC proliferation and 
progenitor cells in vitro and in vivo, is inactivated in gliomas, thus allowing proliferation (Levy et al., 
2008). 
The migration is other important concept related to gliomas. This migratory capacity of 
malignant gliomas represents a relevant challenge to any therapeutic strategy. In the injured adult 
brain, nestin-positive cells migrate to the site of injury from the SVZ, indicating that progenitor cells 
retain the ability to travel through mature parenchyma. This capacity for migration is an essential 
characteristic shared by gliomas and NSC. NSC and NPC appear to be associated with white-matter 
tracts and blood-vessel basement membranes and this is also true for gliomas. These findings 
suggest that NSC and tumour cells share a common substrate for motility (Sanai et al., 2005).  
There are also some glioma-related factors that are also associated with NSC. The VEGF, a 
molecule that stimulates angiogenesis and proliferative potential, is highly produced and secreted by 
glioma cells (Plate et al., 1994). Correspondingly, it was already demonstrated that embryonic NSC 
secrete diffusible VEGF, which underlies their ability to protect endothelial cells against severe 
ischemia and promote angiogenesis in ischemic striatum (Roitbak et al., 2008). Moreover, S100B, a 
calcium-binding protein, has also been referred as a biomarker of some pathological conditions, such 
as brain tumours, since levels of S100B expression are elevated in these disorders (Michetti et al., 
2012). Therefore, being a chemotactic molecule (Bianchi et al., 2011), we can hypothesize that this 
molecule may also perform a pivotal function in tumour cell invasion and metastasis. Along maturation 
of astrocytes from NSC, the expression of S100B is increased, suggesting that S100B expression 
define a late developmental stage after which GFAP-expressing cells lose their NSC potential (Raponi 
et al., 2007). The matrix metalloproteinases (MMP) which have the ability to degrade macromolecules 
of the ECM, have been described as responsible for tumour invasion and infiltration. In gliomas, the 
gelatinases MMP, MMP-2 and MMP-9 show elevated levels of expression, facilitating invasion into the 
surrounding brain and participate in neovascularization (Sun et al., 2012).  Interestingly, a very recent 
study has identified MMP-9 as the molecular effector of increased NSC proliferation and migration in 
lower O2 concentrations, a condition that more appropriately mimic the environment of the neurogenic 
stem cell niche in the developing and adult brain (Bianchi et al., 2011; Ingraham et al., 2011). 
Autophagy is the mechanism responsible for degrading long-lived proteins and cytoplasmic 
organelles, which involves a membranous organelle, the autophagosome (Liu et al., 2011). Moreover, 
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autophagy has a fundamental role in cancer such as in brain tumours. However, perturbations in 
autophagy can contribute to malignant disease. Hence, autophagy can be both oncogenic and tumour 
suppressive, indicating that autophagy has different roles at different stages of tumour development. 
Recent data indicate that this process may play a critical role in the benign to malignant transition,  
also central to the initiation of metastasis (Macintosh et al., 2012). Concerning embryonic 
development, the roles of autophagy are still largely uncharacterized, but there is some evidence 
supporting the existence of a complex interplay between autophagy and cell proliferation during 
mammalian neural development (Fimia et al., 2007). Thus, the process of autophagy in NSC or NPC 
can have a similar role as in glioma cells. 
In summary, the following figure (Fig. I.8) present the main features shared by NSC and glioma 
cells. 
 
 
Fig. I.8 – Shared features by neural stem cells and glioma cells. Cancer research is now being motivated to 
drive its attention to the application of the principles of stem cell biology to the study of human brain tumours, 
such as gliomas, since neural stem cells (NSC) share common features with a specific population of tumour cells, 
the cancer stem cells (CSC). This suggests that NSC or early-differentiated cell type lineages are in the origin of 
gliomas. Addapted from Sanai et al. (2005) 
 
It is important to emphasize that although NSPC or early-differentiated cell type lineages are 
suggested to be in the origin of gliomas, it is not known which developmental stage is more 
susceptible to the malignant transformation. Thus, it will be interesting to investigate which phenotype, 
between NSPC and astroglial cells, along the different developmental stages, have the highest 
tumourigenic potential. By identifying the cell of origin for brain tumours, we will be better equipped to 
understand how the molecular alterations lead to cancer, and how we can target those alterations by 
treatment, or prevent them from occurring.  
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3. Aims 
 
Our general goal was to identify which cell developmental stage, in the NPC differentiation 
process towards astrocytes, is the phenotype most similar to the glioma one, in order to determine and 
better comprehend the cellular pathways that might be involved in gliomagenesis.  
To accomplish this aim, our initial task is to perform primary neurosphere cultures from mouse 
brain cortex at E15 and to subsequently induce astroglial differentiation until 7 days in vitro, 
characterizing the cellular population along the differentiation process regarding markers for stem and 
mature neural cells. Our next task will be to characterize the evolution of some tumour-related factors 
such as the multidrug resistance, the angiogenesis potential, the autophagy ability and the migratory 
capability, as well as the release of metalloproteinases and S100B, in (i) NS, (ii) differentiating 
astrocytes and (iii) in a glioma cell line (GL261). Finally, based on the data obtained, we will identify 
the developmental stage more similar to the glioma cell line.  
 
 
In summary, the tasks to be accomplished in the present thesis encompass: 
 
 1. Primary neurosphere cultures and subsequent differentiation into astrocytes; 
 2. Characterization of the different developmental phenotypes; 
 3. Evaluation of tumour-related factors in glioma cells; 
 4. Identification of the cell developmental stage phenotype more similar to the glioma cell. 
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1. Reactives 
  
1.1 Cell cultures media  
 
Dulbecco’s modified Eagle’s medium (DMEM) was acquired from Biochrom AG (Berlin, 
Germany). RHB-A
TM
 medium was purchased from Stem Cell Sciences (Cambridge, UK)  
 
1.2 Supplements and chemicals  
 
Heat-inactivated chicken serum, trypsin 2.5% (10) and 1 Hanksʼ balanced salt solution 
without Ca
2+
 and Mg
2+
 (HBSS) were acquired from Invitrogen (Carlsbad, CA, USA). Antibiotic 
antimycotic solution (AB/AM) (20), gelatin 2% (bovine skin), deoxyribonuclease I bovine (DNAse I), 
Poly-D-Lysine (PDL), Hoechst dye 33258, 2-mercaptoethanol, bovine serum albumin (fraction V, fatty 
acid free) (BSA), Tris-base, phenylmethylsulfonyl fluoride (PMSF), and propidium iodide [PI; 3,8-
diamino-5-(3-(diethylmethylamino) propyl)-6-phenyl phenanthridinium diiodide], Sigma Fast OPD, 5-
Bromo-2’-Deoxyiridine (BrdU), Coomassie Brilliant Blue R-250 and trypsin-EDTA solution (10x) were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS) was purchased from 
Biochrom AG (Berlin, Germany). Cell lysis buffer
®
 and LumiGLO
®
 were from Cell Signaling (Beverly, 
MA, USA). Murine EGF and murine bFGF (basic fibroblast growth factor) were obtained from 
PeproTech (Rocky Hill, NJ, USA). NaOH, HCl, acrylamide, bis-acrylamide, glycine, glucose anhydre, 
methanol, Giemsa, paraformaldehyde (PFA), and Tween 20 were from Merck (Darmstadt, Germany). 
Sodium dodecyl sulphate (SDS) was acquired to VWR-Prolabo. Nitrocellulose membrane was 
obtained from Amersham Biosciences (Piscataway, NJ, USA). Triton X-100 (100 mL) was from Roche 
Diagnostics (Indianapolis, USA). DPX mountant for microscopy was acquired from BDH Prolabo 
(Bangkok, Thailand).  
 
1.3 Antibodies  
 
Primary antibodies: Rabbit anti-GFAP (1:500), mouse anti-BrdU (1:750), mouse anti-β-actin 
(1:5,000) and monoclonal anti-S100B SH-B1 (1:1,000) were acquired from Sigma-Aldrich. Mouse anti-
HuC/HuD (1:750) from Molecular Probes (Leiden, The Netherlands). Rabbit anti-NG2 (1:200), mouse 
anti-MBP (1:200), rabbit anti-Sox2 (1:500), mouse anti-MAP2 (1:100) and mouse anti-nestin (1:200) 
were obtained from Millipore (Billerica, MA, USA). Rabbit anti-VEGF (1:200 for Western blot assay; 
1:100 for immunocytochemistry), mouse anti-VEGFR-2 (or Flk-1, 1:100) and mouse anti-vimentin 
(1:25) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit anti-LC3B 
(microtubule-associated protein light chain 3) from Cell Signaling (Beverly, MA, USA). Rabbit anti-
GLAST from AbCam (Cambridge, UK ) and polyclonal anti-S100B from Dako (Denmark A/S). 
 
Secondary antibodies: Horseradish peroxidise-labelled goat anti-rabbit IgG (1:5,000) was from 
Santa Cruz Biotechnology and horseradish peroxidise-labelled goat anti-mouse IgG (1:5,000) from 
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Amersham Biosciences. Alexa Fluor
® 
594 goat anti-mouse IgG and Alexa Fluor
®
 488 goat anti-rabbit 
were acquired from Invitrogen. Fluorescein isothiocyanate (FITC) anti-mouse IgG was obtained from 
Vector Labs (Burlingame, CA, USA) 
 
 
2. Equipment 
  
Basic equipment included a fluorescence microscope (model AxioScope A1) with integrated 
camera (AxioCamHRm), AxioScope HBO50 with integrated camera (Leica, model DFC490) and 
optical microscope with phase-contrast equipment (Olympus, model CK2-TR), all purchased from Carl 
Zeiss, Inc. (North America). For Western blot and Zymography assays it was used the Mini-PROTEAN 
3 Multi-Casting Chamber (Bio-Rad Laboratories). For protein quantification it was used a Microplates 
reader (PR 2100 Microplate Reader, Bio-Rad Laboratories). For metalloproteinases gels photos it was 
used the Chemidoc (Bio-Rad Laboratories). Samples sonication for a well homogenization was 
performed in the Ultrasonic Processor UP100H (Hielscher-Ultrasound Technology, Teltow, Germany). 
To ensure a stable ambient to optimal cell growth (37°C and 5% CO2), cell cultures were maintained in 
HERAcell 150 incubator (Thermo Scientific, Waltham, MA, USA) and execution was accomplished in 
sterile conditions using a Holten Lamin Air HVR 2460 (Allerod, Denmark). For flow cytometry studies, 
we used the Guava – Easy Cyte HT model (Millipore). A 48-well microchemotaxis chamber (Boyden 
chamber) and polycarbonate track-etch membranes with polyvinylpyrrolidone (PVP) treatment were 
purchased from Neuro Probe, Inc (Gaithersburg, MD, USA). 
 
 
3. Methods 
 
3.1 Cell cultures and treatments  
 
3.1.1 Primary neurosphere culture of mouse brain cortex at E15  
 
Animal care followed the European Legislation on Protection of Animals Used for Experimental 
and Scientific Purposes (EU directive L0065, 22/07/2003) in order to ensure their well-being and 
minimize animal´s use and suffering.  
Cortical neural precursors were isolated from E15. Briefly, pregnant female mice (CD1, Harlan 
Laboratories, Inc., Indianapolis, USA) at gestational stage E15 were euthanized by asphyxiation with 
CO2. The fetuses were rapidly decapitated and after removal of meninges and white matter, the 
neocortices were collected in 9 mL of HBSS and mechanically fragmented. After chemical dissociation 
with trypsin-EDTA 10% and DNAse I (1 U/mL), the suspension was incubated for 30 min at 37ºC, with 
occasional mixing. Following trypsinization, cells were washed three times with HBSS and 
resuspended in RHB-A
TM
 medium. Cells were then mechanically dissociated using a Pasteur pipette 
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performing more or less 20 passages. Around 1x10
6
 cells/mL were plated onto 24-well uncoated 
tissue culture plates in RHB-A
TM
 medium supplemented with 10 ng/mL of recombinant murine EGF 
and bFGF, to form free-floating NS, maintained at 37ºC in a humidified atmosphere of 5% CO2. After 
48 h, the NS were removed, centrifuged and resuspended in fresh RHB-A
TM
 medium with EGF and 
bFGF. This cellular suspension was plated onto 96-well uncoated tissue culture plates for more 48 h 
under the same temperature and moisture conditions. After this incubation period, a first set of NS was 
removed and chemically dissociated by addition of trypsin 0.1% and mechanically dissociated through 
passages in a pipette. Approximately 7,0x10
5
 cells/mL were incubated in same culture conditions 
(RHB-A, EGF, bFGF) and plated onto culture plates (some of them containing glass coverslips coated 
with PDL) at 37ºC, in a humidified atmosphere of 5% CO2, during appoximately four hours. After that, 
cells plated in coverslips, were fixed with freshly prepared 4% PFA during 20 min and used for 
immunocytochemistry assays, and cells in the wells without coverslips were used for flow cytometry 
studies or lysed for Western blot, while growth medium was removed, centrifuged and stored at -80
o
C 
to evaluate S100B and MMP contents.  
A second set of NS were maintained till astroglial differentiation as described in the next 
Section.  
A schematic overview of cortical neural precursor’s proliferation as floating aggregates and cell 
treatments is depicted Fig. II.1A. 
 
3.1.2 Neurospheres in vitro astroglial differentiation  
NS were rinsed with PBS and dissociated with 1% trypsin by forcing several passages through 
a pipette. After dissociation, single cells were induced to differentiate into astrocytes by plating them 
onto culture plates (some of them containing glass coverslips) in a concentration of approximately 
7,0x10
5
 cells/mL, in DMEM medium supplemented with 10% FBS. Cells were maintained in 
differentiating conditions during 7 days in vitro (DIV), without changing the culture medium. Each day 
of the astroglial differentiation process, cells plated in coverslips were fixed with freshly prepared 4% 
PFA during 20 min and used for immunocytochemistry assays. Collection of the cells was performed 
at several time intervals to be evaluated and compared to those of the glioma phenotype. We decided 
to use 1, 2, 3 and 7 DIV. Cells were then used for flow cytometry studies or lysed for western blot and 
their growth medium was removed, centrifuged and stored at -80
o
C to analyze the respective 
supernatant content in S100B and MMP.  
A schematic overview of astroglial differentiation from NS is presented in Fig. II.1B. 
 
 
 
 
 
 
 
 
 
 
II. MATERIAL AND METHODS 
28 
 
A) 
 
B) 
 
 
 
 
Fig. II.1 - Schematic representation of the experimental model, involving the preparation of primary 
neurosphere culture and the induction of astroglial differentiation. A) Neural precursor cells were obtained 
from embryonic day 15 (E15) CD1 mouse brain cortex, growing as neurospheres in RHB-A medium, in the 
presence of the growth factors epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF ) (10 
ng/mL). After 4 days in vitro (DIV), cells were fixed or lysed for western blot analysis and the respective cell-free 
medium was collected.  B) Astroglial differentiation was induced by 10% fetal bovine serum ( FBS) and the cells 
were cultured until 7 DIV. At 1, 2, 3 and 7 DIV, cells were fixed or lysed for western blot analysis and the 
respective cell-free medium was collected. Cells fixed in 4% paraformaldehyde were used for 
immunocitochemistry assay toward the evaluation of several cellular markers, proliferative potential, vascular 
endothelial growth factor (VEGF) and vascular endothelial growth factor receptor 2 (VEGFR-2) (the last two only 
on NS, 1, 2, 3 and 7 DIV). Total cell extracts from NS, 1, 2, 3 and 7 DIV in differentiating conditions were used for 
Western blot assay to evaluate  the  multidrug resistence-associated protein (Mrp1), VEGF and microtubule-
associated protein light chain 3 (LC3). The cell culture supernatants from NS, 1, 2, 3 and 7 DIV in differentiating 
conditions (salmon from NS, and red from differentiating DIV) was used for S100B and matrix metalloproteinases 
(MMP) evaluation. AB/AM, Antibiotic antimycotic solution; DMEM, Dulbecco’s modified Eagle’s medium 
 
3.1.3 GL261 mouse glioma cell line  
The GL261 was a kind gift from Dr Geza Safrany, from the National Research Institute for 
Radiobiology and Radiohygiene, in Hungary. Cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 38.9 mM glucose, 11 mM sodium bicarbonate, 1% 
penicillin/streptomycin and 10% FBS, at 37ºC and maintained in 5% CO2 conditioned atmosphere 
during 5 DIV. After this period, cells were lysed for Western blot and their growth medium was 
removed, centrifuged and stored at -80
o
C to analyze the respective supernatant S100B and MMP 
contents.  
The cell culture described above was performed by another master student from our lab. 
CD1 mice
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Floating aggregates
0 2      4 DIV     
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Neurospheres
0 1 2                          3                           4                        5                         6           7 DIV
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3.2 Immunocytochemistry 
 
For characterization of the NS and the differentiating cells, an immunofluorescent detection of 
immature/progenitor cells, astrocytes, neurons and oligodendrocytes was performed. Fixed cells were 
incubated with a glycine solution during 10 min at room temperature (RT) and permeabilized with 
0.1% triton solution for 10 min. Cells were then incubated with a blocking solution [10% FBS in Tween 
20-Tris buffered saline (T-TBS, 0.05% Tween 20, 20mM Tris-HCl, 500 mM NaCl, pH 7.5)] for 30 
minutes at RT. Cells were incubated overnight, at 4
o
C, with anti-Sox2 antibody (rabbit, 1:500) and anti-
nestin antibody (rabbit, 1:200) to stain the presence of undifferentiated/immature cells. To identify 
astrocytes, it was used anti-vimentin (mouse, 1:25) antibody (progenitor glial cells) as well as anti-
GFAP (rabbit, 1:500) and anti-GLAST (rabbit, 1:500) antibodies (differentiated astrocytes). To 
evaluate the presence of oligodendrocytes, it was used an anti- neural/glial antigen 2 (NG2) (rabbit, 
1:200) and anti-myelin basic protein (MBP) (mouse, 1:200) antibodies, to evaluate the presence of 
progenitor and mature cells, respectively. To stain progenitor and mature neurons we used an anti-
HuC/D (mouse, 1:750) and anti-microtubule-associated protein 2 (MAP-2) (mouse, 1:100) antibodies, 
respectively. For the determination of VEGF and VEGFR-2 (tumour-related factors), it was used an 
anti-VEGF (rabbit, 1:100) antibody and an anti-VEGFR-2 (mouse, 1:100) antibody, respectively. Cells 
were then incubated with a species-specific fluorescent secondary antibody labeled with FITC (green 
fluorescence), Alexa Fluor
® 
594 goat anti-mouse IgG, or Alexa Fluor
®
 488 goat anti-rabbit, for 90 min 
at RT. For nuclei staining, coverslips were stained with Hoechst dye 33258 during 2 min (Falcao et al., 
2005). Following a final rinse in T-TBS [0.2% Tween 20, 20 mM Tris-HCl (pH 7.5), 500 mM NaCl] and 
dehydration with methanol, coverslips were mounted onto uncoated glass blades using DPX 
mountand and stored at 4
o
C. Finally, pairs of U.V. and fluorescence images of ten random 
microscopic fields (original magnification: 252x) were acquired per sample (Falcao et al., 2007). 
Immune-positive cells for each cell type and total cells were counted to determine the percentage of 
positive nuclei. The resultant values were presented as percentage of positive cells for each staining. 
Table II.1 summarizes the most frequent markers used in the identification of the several cell 
types along differentiation. 
 
Table II.1 – Proteins markers of interest for the characterization of each differentiating neural cell type. 
 
Cellular type Protein
Neural stem/progenitors - Sox2
Nestin
Astrocytes Precursor Vimentin
Differentiated GFAP
GLAST
Oligodendrocytes Precursor NG2
Differentiated MBP
Neurons Precursor HuC/D
Differentiated MAP2
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3.3 Proliferative potential  
 
The proliferative potential of NS and of differentiating cells was determined by quantification of 
BrdU-positive cells. BrdU is a synthetic thymidine analog that incorporates into the DNA when the cell 
is dividing (during the S-phase of the cell cycle). Some of the cells that were plated in coverslips were 
previously incubated with 10 μM BrdU during 3 h, and fixed with 4% of PFA, followed by 30 min 
treatment with HCl 1N at 37ºC. For detection of BrdU
+
 cells identification, we performed thereafter an 
incubation with an antibody against BrdU (mouse, 1:750), and subsequently with a secondary 
antibody (anti-mouse, FITC). 
Another staining methodology was used in parallel to afford a more precise quantification. For 
that, NS and the differentiating cells were removed by tripsin action, counted and distributed to five 
different eppendorfs with an approximate cellular concentration of 5,0x10
5
 cells. After their 
centrifugation at 500 g (4
o
C), cells were fixed with 4% of PFA in PBS during 20 min on ice. After 
another similar centrifugation, supernatants were removed and cells rinsed with PBS. Fixed cells were 
again centrifuged, and after removal of supernatants cells were incubated for 30 min with HCl 1N at 
37ºC for 30 min. After centrifugation, cells were incubated for 20 min with blocking solution (10% FBS 
in T-TBS) on ice. Cells were again centrifuged and incubated with anti-BrdU antibody (mouse, 1:750) 
for 30 min at 4ºC. After new centrifugation, cells were incubated for 20 min, on ice, with an anti-mouse 
antibody labeled with FITC (1:227). After centrifugation, cells were rinsed once and ressuspended in 
PBS. Finally, cellular suspension was plated in a 96-wells plate and submitted to flow cytometry by 
using GUAVA. Results were expressed as percentage of BrdU
+
 cells. 
 
3.4 Western blot assay 
 
Brieffly, total cell extracts were obtained by lysing cells in ice-cold 1x Cell Lysis Buffer plus 1 
mM PMSF for 10 min, on ice and with shaking, followed by sonication during 20 seconds. The lysate 
was centrifuged at 14,000g for 10 min, at 4
o
C, and the supernatants were collected and stored at -
80
o
C. Protein concentration was determined using the Bradford method (Bradford, 1976). Equal 
amounts of protein content were subject to 12% (for LC3B evaluation) or 8% (for Mrp1 and VEGF 
determination) sodium dodecyl sulfate-polyacrilamide gel electrophoresis (SDS-PAGE), running with 
fixed voltage of 80 V for 12% gel and fixed amperage of 50 mA for 8% gel. After running the gel, 
proteins were transferred to a nitrocellulose membrane, and blotted membranes were rinsed once with 
T-TBS and blocked for 1 h at RT with 4% milk in T-TBS for Mrp1 detection and 5% milk T-TBS for 
LC3B and VEGF evaluations. Membranes were then incubated overnight at 4ºC with a specific Mrp1 
rabbit antibody (1:750 in blocking solution), a specific LC3B rabbit antibody (1:1000 in 5% of BSA in T-
TBS solution) and a specific VEGF rabbit antibody (1:200 in 5% BSA in T-TBS solution). After washing 
three times with T-TBS, the membranes were incubated with HorseRadish Peroxidase (HRP)-labeled 
anti-rabbit (1:5,000) in blocking buffer, for 1 h, at RT.  Again, after washing membranes with T-TBS, 
chemiluminescent detection was performed by LumiGLO® and bands were visualized by 
autoradiography with Hyperfilm ECL. The relative intensities of protein bands were analyzed using the 
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Image Lab
TM
 analysis software, after scanning with Chemidoc, both from Bio-Rad Laboratories 
(Hercules, CA, USA) (Fernandes et al., 2006). 
 
3.5 Gelatin Zymography 
 
The assay was performed as previously described by Silva et al. (2010). MMP quantification 
was performed through the gelatin zymography method, in which the protease activity is directly 
observed in the running gel based on the absence of color (white bands), at the particular site of 
protease action. For this determination, aliquots of culture supernatants were analyzed by SDS-PAGE 
zymography in 0.1% gelatin/10% acrylamide gels under non-reducing conditions, at 20 mA/gel. After 
electrophoresis, gels were washed for 1 h with 2.5% Triton X-100 (in 5 mM Tris pH7.4; 5 mM CaCl2; 1 
μM ZnCl2) to remove SDS and renature the MMP species in the gel. Then, gels were incubated 
overnight in the developing buffer (5 mM Tris pH7.4; 5 mM CaCl2; 1 μM ZnCl2) to induce gelatin lysis. 
For enzyme activity analysis, the gels were stained with 0.5% Coomassie Brilliant Blue R-250 and 
distained in 30% ethanol/10% acetic acid/H2O. Gelatinase activity, detected as a white band on a blue 
background, was photographed in Chemidoc and analyzed using the Image Lab
TM 
software. Results 
were normalized with total protein concentration (Silva et al., 2010). 
 
3.6 ELISA 
 
S100B concentration released into the culture media was determined by ELISA (enzyme-linked 
immunosorbent assay). Initially, 100 µl of a capture antibody (monoclonal antibody anti-S100B SH-B1, 
diluted at 1:1000 in carbonate-bicarbonate buffer 50 mM, pH 9.5) was placed in each well of a 96-well 
plate and incubated overnight at 4
o
C. After this incubation period, the 96-wells plate was rinsed three 
times with wash buffer (0.1% BSA with 0.05% Tween) and incubated with blocking solution (2% BSA 
in PBS) for 1 h at RT. The plate was again washed once with the buffer and samples added and 
incubated for 2 h at 37ºC. Following three washes with wash buffer/well, samples were incubated with 
the detection antibody (polyclonal antibody anti-S100B, diluted at 1:5,000 into 0.5% BSA with 0.2 mM 
CaCl2 in PBS) for 30 min at 37
o
C. Finally, after three new washes, an anti-rabbit peroxidase-
conjugated antibody (1:5,000) was added for further 30 min at 37ºC. Then, more three washes were 
done with wash buffer. The 96-well plate was washed once more with PBS, and the substrate solution 
was added and followed by an incubation of 30 min at RT (Leite et al., 2008). The colorimetric reaction 
with Sigma Fast OPD tablets was measured at 492 nm, using the microplate reader and results were 
expressed in ng/mL.  
 
3.7 Migration Assay 
 
This method was originally adapted from the protocol reported by Nolte et al. (1996) and, after 
several attempts and failures, some modifications led to the optimization of this method by our group. 
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The migratory potential was evaluated only in NS and differentiating cells with 1 and 7 DIV and it was 
compared with the one of glioma cells. NS in suspension were centrifuged, dissociated with the aid of 
tripsin for 1 min at 37
o
C, counted and plated accordingly to the schematic representation of Fig.II.2. 
The remaining cells were washed once with PBS and incubated with trypsin for 2 min at 37
o
C, 
centrifuged, counted and plated as depicted in Fig. II.2. 
Cell migration assays were performed in a 48-well microchemotaxis chamber. Initially, each of 
the bottom wells of the Boyden chamber was loaded with 25 µl of VEGF solution (20 ng/mL in RHB-A 
or DMEM medium) or 25 μl of glioma growth media (see Fig.II.2). Thereafter, a PVP-treated 
polycarbonate filter (8 μm pore size), previously moistened with RHB-A or DMEM, was placed over 
bottom wells. After addition of the upper plate, both bottom and upper wells were only separated by 
the membrane between them. The cells (1.5x10
4 
cells/well) were thoroughly added in 50 µl of RHB-A 
(for neurospheres) or DMEM (for differentiating astrocytes and glioma cells) and incubated at 37
o
C for 
5 h (Schmidt et al., 1999). The filter was removed, fixed with methanol during 3 min and after drying, 
stained for 30 min at RT with freshly prepared and filtered 10% Giemsa in phosphate buffer. Finally, 
the excess color from the side filter without cells (upper) was carefully clean and the filter/membrane 
was mounted on a glass slide. Image of one microscopic field (original magnification: 100X) was 
acquired per well using a Leica DFC490 camera adapted to an AxioSkope® microscope and the 
number of cells was counted. On each experiment at least three wells were sampled per condition. 
 
 
 
Fig. II.2 – Schematic representation of the migration assay. A) For the determination of migration levels to 
vascular endothelial growth factor (VEGF), neurospheres (NS) in RHB-A
TM
 medium (orange), 1 and 7 days in vitro 
(DIV) differentiating astrocytes in DMEM (Dulbecco’s modified Eagle’s medium) media (red) as well as glioma 
(GL) cells with 5 DIV in DMEM media (red) were plated in the upper chamber, while in the lower chamber (in 
corresponding wells) it was only added media (control) or 20 ng of VEGF in media. B) For the determination of 
migration cell capacity to conditioned glioma cells media, NS, 1 and 7 DIV differentiating astrocytes were 
ressuspended in DMEM and plated in the upper chamber, while in the lower chamber (in corresponding wells) it 
was only added DMEM (control) or media from glioma cells with 5 DIV. All experiments were performed in 
triplicate.  
 
4. Statistical analysis  
 
Results of at least, three different experiments performed in duplicate, were expressed as mean 
± SEM. Differences between groups were determined by one-way ANOVA with Dunnett’s multiple 
comparisons post tests, using Instate 5.01 GraphPad software (San Diego, USA). It was considered p 
<0.05 as statistically significant. 
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NSC have been described as a potential origin of some brain tumours. Due to the sharing of 
several common features between NSC or NPC and glioma cells [such as the longevity, high motility, 
proliferative capacity (Ignatova et al., 2002; Sanai et al., 2005), and pluripotency (Louis et al., 2007; 
Tan et al., 2006)] it is thought that gliomas (particularly astrocytomas) can be originated by malignant 
transformation of NSC or NPC, or by the occurrence of modifications in the normal course of 
differentiation of glial NPC (Sanai et al., 2005). This malignity may be related with a phenotype that will 
most resemble glioma cells.  Thus, it was evaluated some tumour-related factors to investigate which 
developmental stage, in the NSC differentiation process towards astrocytes, possessed the highest 
number of tumourigenic characteristics most similar to glioma cells. 
 
1. Characterization of neurospheres and of the different developmental 
phenotypes 
 
Primary cultures of NS obtained from CD1 mice cortices at E15 were cultured in the proliferation 
media and induced to differentiate into astrocytes, as described in methods. NS were characterized 
regarding their cellular composition and concerning the phenotype originated throughout the 
differentiation process into astrocytes, by immunocytochemistry assays. The results reflected the 
efficacy of the differentiation method and allowed us to identify and select the phenotypes to be used 
in the tasks that will follow. 
  
1.1 Differentiation of NS into astrocytes leads to a reduction in the undifferentiated 
cell markers Sox2 and nestin  
 
The percentage of an immature phenotype in NS and differentiating cells was determined using 
antibodies against undifferentiated/immature cell markers, such as Sox2 and nestin. We could 
observe that the expression of both proteins decreased throughout differentiation (Fig. III.1). The 
expression of these two proteins was more abundant in the NS and gradually was reduced with the 
advance of differentiation. Regarding specifically Sox2, there was a regular decline through the 
differentiation process, culminating in a 50% decrease at 7 DIV cells (p<0.01). For nestin, there was 
also an overall reduction; however, this reduction was very abrupt from 1 DIV to 2 DIV (p<0.01) 
followed by a continuously decrease. As expected, while the Sox2 fluorescent staining (green) 
localized in the nuclei, the majority of nestin (red) protein was spread in the cytoplasm. 
 Overall, these results indicate that the number of immature cells decrease along differentiation, 
and that nestin expression is more rapidly reduced when compared with the Sox2 one.  
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Fig. III.1 – Expression of immature phenotypes during proliferation and along differentiation. Cells were 
cultured as indicated in methods. A) Nuclei were stained with Hoechst dye (blue) and cells labeled for Sox2 
(green) and Nestin (red). Representative results from one experiment are shown. B) Graph bars represent the 
percentage of cells (mean ± SEM) positive for Sox2 (black) and nestin (grey), relatively to the total number of 
nuclei. Data were obtained from at least three independent experiments. **p<0.01 vs. neurospheres (NS). DIV, 
days in vitro under differentiating conditions. Scale bar represents 60 µm. 
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1.2 Differentiation of NS into astrocytes leads to a reduction of BrdU, a marker of 
proliferating cells 
 
The proliferative potential was evaluated through the incubation of cells with BrdU and further 
immunostaining with an antibody against BrdU, in order to determine the percentage of the BrdU-
positive cells in NS and along astrocyte differentiation. The image presented in Figure III.2.A shows 
that the number of BrdU-positive cells decreases along differentiation. Based on the results obtained 
in the previous section, the immature cells are those showing the highest proliferative potential. There 
is an evident decrease in proliferation from NS stage to 1 DIV cells (0.5-fold, p<0.01), followed by a 
more gradual and less pronounced reduction in BrdU-positive cells from 1DIV to 7 DIV. 
Immunostaining results (Fig. III.2B) were further corroborated when the flow cytometry (GUAVA) 
method was used (Fig.III.2C), which showed a similar result profile.   
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Fig. III.2 – Expression of proliferative potential during cell division and differentiation. Cells were cultured 
and treated as indicated in methods. A) Results obtained from immunocytochemistry assay. Nuclei were stained 
with Hoechst dye (blue) and cells labeled for 5-bromo-2'-deoxyuridine (BrdU, green). Representative results from 
one experiment are shown. B) Graph bars represent the percentage of cells (mean ± SEM) positive for BrdU, 
relatively to the total number of nuclei. Data obtained from at least three independent experiments. C) Results 
obtained from flow cytometry (GUAVA) evaluation. Graph bars represent the percentage of cells (mean ± SEM) 
positive for BrdU. Data obtained from at least three independent experiments. **p<0.01 vs. neurospheres (NS). 
DIV, days in vitro under differentiating conditions. Scale bar represents 60 µm. 
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1.3 Differentiation of NS into astrocytes leads to a reduction in the early astrocytic 
progenitor marker vimentin and an increase in the astrocytic markers GFAP and 
GLAST 
 
The number of cells with astrocytic features cells in NS and differentiating stages was 
determined using antibodies against vimentin, to identify astrocytic-progenitor cells, as well as against 
GFAP and GLAST to identify astrocytes. It was observed that the expression of vimentin decreased 
throughout differentiation, while the expression of GFAP and GLAST increased. Immunocytochemistry 
showed that the localization of all proteins was cytoplasmic (Fig. III.3). Regarding the number of 
vimentin-positive cells, although no significant differences, it gradually increased until 2 DIV (1.3-fold 
vs. NS), decreasing almost 50% thereafter, a value that was maintained from 5 to 7 DIV. Interestingly, 
although GLAST-positive cells increased more rapidly than the number of GFAP-positive cells 
(maximal levels at 7 DIV), the incremental peak achieved at 7 DIV was only 2.8-fold higher (p<0.01) 
than the one obtained in NS, while that for  GFAP-positive cells was 3.8-fold higher (p<0.01). These 
results demonstrate that the cell population at 7 DIV are mostly cells with astrocytic features and that 
the astrocytes progenitors are replaced by mature-astrocytes throughout differentiation, since the 
number of differentiated astrocytes increases appreciably when the number of vimentin-positive cells 
decrease. Overall, these results reveal that our differentiation method into astrocytes was efficient and 
appropriate to the intended objective of obtaining this preferential cell type.  
 
1.4 Differentiation of NS into astrocytes leads to an highly decrease in the 
oligodendroglial markers NG2 and MBP 
 
The number of cells with oligodendroglial features in both NS and differentiating cells was 
determined using the antibodies against oligodendroglial progenitor cells and oligodendroglial mature 
cells markers, NG2 and MBP (myelin basic protein), respectively.  It was observed that the expression 
of both proteins undergoes a prominent decrease throughout differentiation and that the localization of 
the both proteins was cytoplasmic (Fig. III.4). The number of oligodendroglial progenitors (NG2-
positive cells) was higher in NS (approximately 13% of positive cells) than the percentage registered 
along differentiation (p<0.01). On the other hand, MBP-positive cells (mature oligodendroglia) appear 
only at 3 DIV with a percentage less than 1%. This low percentage is observed throughout all the 
differentiation process in spite of a slight increase from 3 to 5 DIV. This evaluation allowed us to verify 
that oligodendrocyte-like cells are scarcely represented along the differentiation process. 
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B) Fig. III.3 – Vimentin-expressing 
astrocytes-progenitor and 
GFAP and GLAST-expressing 
astrocytes observed during 
proliferation and along 
differentiation. Cells were 
cultured as indicated in methods. 
A) Nuclei were stained with 
Hoechst dye (blue) and cells 
labeled for vimentin, glial fibrillary 
acid protein (GFAP) and 
glutamate aspartate transporter 
(GLAST). Representative   results 
from one experiment  are   
shown.  
B) Graph bars represent the percentage of cells (mean ± SEM) positive for vimentin, GFAP and GLAST, 
relatively to the total number of nuclei. Data obtained from at least three independent experiments. *p<0.05 and 
**p<0.01 vs. neurospheres (NS).  DIV, days in vitro under differentiating conditions. Scale bar represents 60 µm. 
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1.5 Differentiation of NS into astrocytes leads to a highly decrease in the neuronal 
markers HuC/D and MAP2 
 
The percentage of cells with neuronal features in both NS and differentiating stages were 
determined using antibodies against neuronal progenitor cells (HuC/D) and against neuronal mature 
cell markers (MAP2), respectively. Immunocytochemistry showed that the cellular localization of the 
both proteins were different, i.e., while HuC/D (red) had a nuclear localization, the MAP2 (green) was 
noticed at the cytoplasm and stained the neuronal ramifications (Fig. III.5). As expected, both the 
number of neuronal progenitor cells (HuC/D-positive cells), as well as the number of MAP2 positive 
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Fig. III.4 – Expression of the oligodendroglial 
phenotypes during proliferation and along 
differentiation. Cells were cultured as indicated in 
methods. A) Nuclei were stained with Hoechst dye 
(blue) and cells labeled for NG2 (oligodendroglial 
progenitors, green) and myelin basic protein (MBP, 
mature oligodendrocytes, red). Representative 
results from one experiment are shown. B) Graph 
bars represent the percentage of cells (mean ± 
SEM) positive for NG2 and MBP, relatively to the 
total number of nuclei. Data obtained from at least 
three independent experiments. *p<0.05 and 
**p<0.01 vs. neurospheres (NS).  DIV, days in vitro 
under differentiating conditions. Scale bar 
represents 60 µm. 
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cells was low in NS (approximately 5% of positive cells). In addition, both proteins revealed a similar 
expression profile, but at different time points along differentiation. Thus, for HuC/D, it was observed 
an increase in the number of positive cells until 4 DIV (7.0-fold vs. NS), followed by a reduction that 
achieved the lower value at 7 DIV (2.0 fold vs. NS). On the other hand, the number of MAP2-positive 
cells that slightly increased up to 2.0-fold, as compared to NS at 1 DIV (ns) was also followed by a 
decrease till 6 to 7 DIV. These results evidence that despite the presence of neuronal progenitors 
along all the differentiation process (particularly at 4 DIV), it seems that these cells are not able to 
further differentiate into mature neurons, as the number of MAP2 positive cells was maintained always 
very low. 
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B) Fig. III.5 – Expression of the neuronal 
phenotypes during proliferation and along 
differentiation. Cells were cultured as 
indicated in methods. Nuclei were stained with 
Hoechst dye (blue) and cells labeled for 
HuC/D (neuronal progenitors, red) and 
microtubule-associated protein 2 (MAP2, 
mature neurons, green). Representative 
results from one experiment are shown. B) 
Graph bars represent the percentage of cells 
(mean ± SEM) positive for HuC/D and MAP2, 
relatively to the total number of nuclei. Data 
obtained from at least three independent 
experiments. NS, neurospheres;  DIV, days in 
vitro under differentiating conditions. Scale 
bar represents 60 µm. 
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Collectively, the results obtained for cellular characterization allowed the selection of the stages 
NS, 1, 2, 3 and 7 DIV as the best to be used in the experiments to be realized in the next task.  We 
excluded the time points 4, 5 and 6 DIV because no significant changes were obtained from 3 DIV and 
7 DIV regarding the markers that we used.  Moreover, as shown, the values found for 4, 5 and 6 DIV 
were very similar, thus turning irrelevant further evaluations on these phenotypes, and also 
considering that the largest modification for astrocytes markers was obtained from 3 DIV to 7 DIV, 
thus attesting the high prevalence of mature astrocytes.  
 
 
2. Comparison between tumour-related factors in glioma cells and in the 
successive developmental phenotypes from neurospheres 
 
For this part of the work it was used not only the cells obtained from primary NS, and cells from 
the subsequent steps of differentiation (described in the previous section), but the mouse glioma cell 
line GL261, as well. This cell line is representative of a carcinogen-induced mouse syngeneic glioma 
model (Newcomb and Zagzag, 2009). The GL261 tumour was originally induced by intracranial 
injection of 3-methylcholantrene into C57BL/6 mice and maintained by serial intracranial and 
subcutaneous transplantations of small tumour pieces on the syngeneic mouse strain (Ausman et al., 
1970; Szatmari et al., 2006). These cells have invasive and angiogenic properties and present growth 
features similar to the human GBM, thus representing an important tool to study the biology of this 
type of human cancer (Newcomb and Zagzag, 2009). 
 
2.1 Cells from NS reveal levels of Mrp1 expression very similar to those of glioma 
cells  
 
The Mrp1 expression levels in NS, differentiating cells and GL261 was determined by Western 
blot assay, using an antibody against Mrp1, normalized against the corresponding β-actin levels. It 
was observed that the expression of Mrp1 was significantly higher in NS as compared to differentiating 
cells (p<0.01, except in 7 DIV) (Fig. III.6). Thus, the expression profile revealed a decrease of Mrp1 
from NS to 1 DIV that proceeded until 3 DIV, were the lowest value was obtained (0.5-fold vs. NS, 
p<0.01). Despite the elevation next observed at 7 DIV, and although no significant differences, the 
values were still lower than those obtained in NS (0.7-fold vs. NS). Most interesting, although the 
GL261 cells have shown the highest values for Mrp1 expression they were not more elevated than the 
levels obtained in NS. The results, therefore, indicate that NS are the cells that most closely resemble 
the glioma cells in terms of the Mrp1 expression. 
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2.2 Cells differentiated during 24 h from NS are those exhibiting autophagic levels 
most similar to the ones observed in glioma cells 
 
Autophagy is an intracellular lysosomal degradation process, which plays an important role in 
cell growth and development (Chen et al., 2012). Autophagic activity evidenced to be decreased in 
glioma stem/progenitor cells (Zhao et al., 2010) and when induced demonstrated to turn cells more 
sensitive to radiotherapy (Zhuang et al., 2012). LC3 conversion (LC3-I to LC3-II, expressed by LC3II/I 
ratio) was assayed by Western blot, given their different mobilities, as a biomarker of the autophagy. 
While LC3-I is cytoplasmic, LC3-II is autophagosome membrane-associated (Kabeya et al., 2000; 
Mizushima, 2007). Autophagic activity was assessed in GL261 and in differentiating cells from NS, 
using an anti-LC3 antibody, and the results normalized against β-actin levels (Fig. III.7). Conversion of 
LC3-I to LC3-II demonstrated to increase from NS to 7 DIV differentiated cells (2.8-fold vs. NS). 
Although only one experiment was accomplished, and based that GL261 cells showed a 2.1-fold 
increase in LC3II/I expression, as compared to NS, we may hypothesize that similarities between 
GL261 and differentiating cells are better at 1DIV cells that also evidenced a 2.2-fold vs. NS. Thus, in 
what concerns the claimed decreased levels of autophagy in glioma cells equivalent values were 
observed in cells after 24 h of differentiation from NS (1 DIV). 
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Fig. III.6 – Comparison of Mrp1 expression 
in neurospheres and differentiating 
astrocytes with that in glioma cells. Cells 
were cultured as indicated in methods.  Total 
cell lysates were analyzed by Western blot 
with antibody specific for multidrug resistance 
protein 1 (Mrp1).  Representative results from 
one experiment are shown. Similar results 
were obtained in at least three independent 
experiments. The   intensity of the bands was 
quantified by scanning densitometry, 
standardized with respect to -actin protein 
and expressed as mean ± SEM fold change 
compared to naurospheres (NS).  *p<0.05 
and **p<0.01 vs. NS; 
##
p0.01 vs. GL261 
cells.  DIV, days in vitro under differentiating 
conditions. 
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2.3 Glioma cells evidence higher levels of VEGF and VEGFR-2 expression than NS 
or differentiating astrocytes 
 
The expression level of VEGF in NS, differentiating cells and GL261 cells was determined by 
both Western blot and immunocytochemistry, using an antibody against VEGF. The expression level 
of VEGFR-2 (vascular endothelial growth factor receptor 2) was determined through 
immunocytochemistry, using an antibody against VEGFR-2 (Flk-1). As shown in Figure III.8A the 
staining for VEGF (green) is mostly nuclear and the intensity of fluorescence changes along 
differentiating days in vitro, with values more elevated in NS and in the first stages of cell 
differentiation, peaking at 2 DIV (1.3-fold vs. NS) although no significant differences. The lowest 
values were observed at 7 DIV, representing about 50% of the one obtained in NS (p<0.01). GL261 
cells, in contrast, exhibited 2.6-fold higher values than NS (p<0.01), attesting its angiogenesis potential 
and glioma growth abiliy.  A similar profile was obtained for VEGFR-2, the most important receptor in 
the direct regulation of angiogenesis and expressed at high levels in glioma (Sharma and Saad, 
2011), as depicted in Figure III.8A. Staining of VEGFR-2 (red) is mainly cytoplasmic and like VEGF 
the highest value was observed at 2 DIV cells (1.3-fold vs. NS) with the 7 DIV cells presenting the 
lowest value (less than 50% of NS, p<0.01), but even so always less than a half of the expression in 
GL261 cells (2.7-fold vs. NS, p<0.01) and  therefore, none of the several stages of differentiation or 
NS was even close of the VEGF and VEGFR-2 values obtained in GL261. However, although 
significantly different (p<0.05), the expression for both VEGF and VEGFR-2 at 2 DIV cells was the one 
closer to GL261 cells. Curiously, as the immunocytochemistry assay evidence, a higher expression of 
VEGFR-2 than VEGF was obtained in NS and progenitor phenotypes.  
Despite the reduced number of experiments (n=2) and the elevated standard error of the mean 
(mainly for GL261 experiments) the VEGF expression by Western blot revealed a profile similar to the 
immunocytochemistry assay (Fig. III.8B). However, this assay revealed values of VEGF in GL261 
almost 3 times more elevated than those in the previous immunocytochemistry determination (7.6-fold 
vs. NS). 
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Fig. III.7 – Comparison of the LC3-I to LC3-
II expression conversion between the 
different stages from neurospheres to 
differerentiated astrocytes and glioma 
cells. Cells were cultured as indicated in 
methods. Total cell lysates were analyzed by 
Western blot with an antibody specific for 
microtubule-associated protein light chain 3 
(LC3). The intensity of the bands was 
quantified by scanning densitometry, 
standardized with respect to -actin protein 
and expressed as fold change vs. 
neurospheres (NS). Data was obtained from 
only one experiment. DIV, days in vitro under 
differentiation. 
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Fig. III. 8 – Comparison of VEGF and VEGFR-2 
expression between neurospheres plus the 
astrocytes differentiation stages and the glioma 
cells. Cells were cultured as indicated in methods. A) 
Nuclei were stained with Hoechst dye (blue) and cells 
labeled for vascular endothelial growth factor (VEGF, 
green) and vascular endothelial growth factor receptor 
2 (VEGFR-2, red). Graph bars represent the fold 
changes (mean ± SEM) for positive VEGF and 
VEGFR-2 cells, relatively to the total number of nuclei. 
Data obtained from at least three independent 
experiments. Scale bar represents 300 µm. *p<0.05 
and **p<0.01 vs. neurospheres (NS); 
#
p0.05 and 
##
p<0.01 vs. GL261 cells. B) Total cell lysates were 
analyzed by Western blot with specific antibody for 
VEGF. The intensity of the bands was quantified by 
scanning densitometry, standardized with respect to -
actin protein and expressed as mean fold change 
compared to NS, assumed as 1. Data was from only 
two experiments. DIV, days in vitro under 
differentiation. 
B) 
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2.4 MMP-9 and MMP-2 expression levels in glioma cells are more similar to the 
ones in 1 and 7 DIV differentiating astrocytes   
 
The concentration of MMP-9 and MMP-2 in NS, differentiating astrocytes and GL261 cells was 
determined by gelatin zymography (Fig. III.9A). Results were normalized to the correspondent total 
protein concentration (Figs. III.9B and C). The activity of MMP-9 evidenced maximal levels in the 
differentiating cells at 2 DIV (1.9- fold vs. NS, p<0.01) decreasing thereafter until 7 DIV (1.6-fold vs. 
NS, p<0.01). The lowest values for MMP-9 activity were seen in NS that evidenced to significantly 
differ from the levels obtained in GL261 cells (1.8-fold vs. NS, p<0.05). All the other results obtained 
were higher than those in GL261 and, although only significantly increased at 2 and 3 DIV. Again, but 
now for the activity of MMP-2, the lowest value was also observed in NS that significantly differed from 
all the other differentiating temporal windows and even glioma cells that showed to be 1.8-fold 
enhanced as compared to NS (p<0.05). The highest level was obtained at 3 DIV (2.4-fold vs. NS, 
p<0.01), which was again superior to that of MMP-2 in GL261 cells. 
In summary, the 1 and 7 DIV differentiated astrocytes were the ones closer to the GL261 cells 
in what concerns to both MMP-2 and MMP-9 levels.    
 
 
 
 
 
 
 
 
Fig. III.9 – Comparison of matrix metalloproteinase-9 (MMP-9) and MMP-2 activities between neurospheres 
plus the astrocytes differentiation stages and the glioma cells. Cells were cultured as indicated in methods. 
Conditioned media was collected from neurospheres (NS) and from all cells at the several differentiating windows, 
as well as from GL261 cells line for quantification of MMP activity. A) MMP-2 and MMP-9 were identified by their 
apparent molecular mass of 72 and 92 kDa, respectively. Representative results from one experiment are shown. 
B) and C) Graph bars represent the intensity of the bands quantified by scanning densitometry and standardized 
with respect to protein quantification for MMP-2 and MMP-9, respectively. Results are expressed as mean ± SEM 
from at least three independent experiments, and presented as fold change relatively to NS, assumed as 1.  
**p<0.01 vs. NS; 
#
p0.05 vs. GL261 cells. DIV, days in vitro under differentiation. 
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2.5 Evaluation of S100B protein expression by NS/differentiating astrocytes and its 
comparison with glioma cells 
 
The extracellular concentration of S100B in NS, differentiating astrocytes and GL261 cells was 
determined by ELISA, and normalized to the respective total protein concentration. Results depicted in 
Figure III.10 evidence that the release of S100B by NS is almost null (~0.1nM), in opposite to all the 
other results found, which revealed to be markedly more elevated. However, with the exception of the 
values obtained for 2 DIV cells (p<0.01 vs. NS) all of them were significantly lower than the ones 
exhibited by the GL261 cells (~1µM). These cells evidenced the highest amount of S100B released to 
the extracellular media and the concentration obtained from the 2 DIV cells (p<0.05 vs. GL261) was 
the one closer to GL261 cells. 
 
 
 
 
2.6 Migratory potential of NS and differentiating astrocytes are higher than that of 
glioma cells  
 
The migratory capability was evaluated through the Boyden chamber assay described in section 
II.3.7. Here, two different parameters were evaluated, answering to two different questions. Firstly, it 
was determined the migratory properties of NS, as well as 1 DIV and  7 DIV differentiating astrocytes, 
and GL261 cells towards VEGF, a growth factor described as an important chemoattractant present in 
the tumour mass. Using this experimental design we evaluated the developmental stage that 
evidenced the migratory potential most similar to GL261 cells. Secondly, it was evaluated the ability of 
NS, as well as 1 DIV and 7 DIV differentiating astrocytes to migrate towards GL261-conditioned 
media. In this case, we will investigate which developmental stage present the higher tropism to 
glioma cells. 
We start by evaluating the most suitable cell concentration to be used in the migration assay. 
Thus, two different cellular concentrations were tested: 1.5 x 10
4
 cells/well and 3.0 x 10
4
 cells/well. 
First concentration has revealed to be the most adequate because at higher cell number the NS easily 
form aggregates, which prevent them from crossing the membrane pores, thus forming visible blots on 
the upper face of the membrane (results not shown). It was also tested which VEGF concentration 
Fig. III.10 – Comparison between S100B 
release levels from neurospheres, 
differentiating astrocytes and glioma cells. 
Cells were cultured as indicated in methods. 
Conditioned media was collected from 
neurospheres (NS) and from all cells at the 
several differentiating windows, as well from 
GL261 cell line for quantification of S100B 
concentration by ELISA assay. Graph bars 
represent the extracellular concentration of S100B 
protein expressed as mean ± SEM from at least 
three independent experiments, and presented as 
fold change compared to NS, assumed as 1. 
**p<0.01 vs. NS; 
#
p0.05 and 
##
p<0.01 vs. GL261 
cells. DIV, days in vitro under differentiation. 
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was the most suitable to be used in the studies. It were tested 1, 2.5, 5, 10 and 20 ng/mL 
concentrations, and that of 20 ng/mL VEGF concentration was the one selected for the assays (results 
not shown). Regarding the evaluation of migratory potential towards VEGF (Fig. III.11A), we observed 
no differences between NS and the differentiating cells but unexpectedly GL261 cells evidenced  the 
lowest ability when compared to the first, although no significant differences (Fig. III.10B). A slightly 
higher migratory capacity was shown by 1 DIV cells (ns). These cells were also the ones that exhibited 
the greater capacity to migrate towards GL261-conditioned as depicted in Figures III.11A and C.   
 
 
 
 
 
Fig. III.11 – Comparison of the migratory potential between neurospheres plus the astrocytes 
differentiation stages and the glioma cells towards VEGF and GL261-conditioned media.  Cells were 
cultured as indicated in methods. Migration was performed using a Boyden Chamber and the cells migrated for 5 
h, crossing a PVP-treated polycarbonate filter (8 μm pore size) as described in methods. Representative results of 
one experiment evidencing the migrated cells (pink, indicated by black arrow), are shown in (A). The total number 
of cells per well that migrated to 20 ng vascular endothelial growth factor (VEGF) (B) and to GL261-conditioned 
media (GL261-CM) (C) were counted and the results expressed as fold change vs. control. Results are mean (± 
SEM) from at least three independent experiments performed in triplicate. Scale bar represents 100 μm. DIV, 
days in vitro under differentiation. 
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NSC can be isolated from the fetal or adult brain and expanded in culture through NS, which 
have the ability to generate neurons, astrocytes and oligodendrocytes (Sergent-Tanguy et al., 2006; 
Sun et al., 2011; Suzuki et al., 2004). Our results show that the cellular mass obtained from primary 
culture of cortex fetuses at E15, when maintained in proliferation conditions with growth factors, give 
rise to the formation of NS. As previously described by some groups, the data obtained from the 
immunocytochemistry assays performed in the present study evidence that NS are really heterogenic 
as they are composed by a mixture of both undifferentiated and differentiated cell types (Bonnamain et 
al., 2012; Breier et al., 2010; Garbossa et al., 2012).  
It is described that Sox2 and Nestin are the proteins most expressed by NS as cell markers of 
undifferentiated cells (Abe et al., 2006; Bani-Yaghoub et al., 2006; Brunet et al., 2004), thus confirming 
these cells as NSC. Likewise, Sox2- and Nestin-positive cells are also BrdU-positive (Bani-Yaghoub et 
al., 2006; Sun et al., 2011). Results here presented are consistent with those observations, since our 
NS cultures express high levels of Sox2 and Nestin, being the two most representative cell markers at 
this stage of development. Associated to their proliferative potential, BrdU also had a high level of 
staining in NS, confirming that these undifferentiated cells have the capability to maintain cellular self-
renewal and expansion. The BrdU-positive cells had a percentage most similar to Nestin-positive cells, 
and lower than the Sox2-positive cells. These results are in agreement with data from Sun et al. 
(2011) showing that BrdU-positive cells are also nestin-positive cells, and from Bani-Yaghoub et al. 
(2006) evidencing that not all Sox2-positive cells are BrdU-positive ones. Besides revealing the 
undifferentiated cell markers, NS also show a small amount of markers characteristic of differentiated 
cells. Thus, we found that NS express astroglial-markers, such as vimentin which is specific for glial 
progenitor cells, GLAST that is expressed by early progenitor astrocytes (and other glial cells) and 
lately by mature astrocytes, as well as GFAP that is expressed in differentiated astrocytes or in 
differentiation. However, vimentin has a higher expression level in NS than GFAP or GLAST, leading 
us to conclude that there is an elevated percentage of early progenitor astrocytes in NS. These data is 
supported by previous results describing high levels of vimentin in NPC (Chan-Ling et al., 2009), and 
Sox2 and Nestin co-expression (Li et al., 2011). Preceding studies have demonstrated GFAP 
expression on these floating aggregates from several mouse brain tissues (Brazel et al., 2005; Breier 
et al., 2010; Rieske et al., 2007), which are in accordance with our own results. Regarding GLAST-
positive cells, our data is similar to that of Brunet et al. (2004) that also show GLAST expression in 
NS. Since earlier studies showed a decrease of vimentin expression when GFAP expression increase 
(Chan-Ling et al., 2009; Liu et al., 2002), and given that GLAST stain early progenitor astrocytes, their 
sequential order of expression is: first the vimentin marker, followed by the GLAST marker and finally 
the GFAP one as we found, since we obtained in NS a higher percentage of vimentin expression, 
followed by GLAST and finally the GFAP expression, the less pronounced astrocytic cell marker.  
The immunostaining of oligodendrocytic cells in our NS culture indicated the presence of 
oligodendroglial progenitors (NG2-positive cells) but not of oligodendroglial mature cells (MBP-positive 
cells). The presence of NG2-positive cells in NS is also described in the literature (Brazel et al., 2005; 
Machon et al., 2005) and indicated as corresponding to near 10%, a value very similar to that obtained 
by us. The absence of mature oligodendrocytes in NS is not surprising as it is known that maturation 
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of oligodendrocytes takes place only in early postnatal life (Baumann and Pham-Dinh, 2001), a stage 
where cells are already differentiating instead of being in a proliferation stage.  
Finally, the evaluation of neuronal cells in our NS culture indicated that the presence of 
neuronal progenitor cells (HuC/D-positive cells) is higher than neuronal mature cells (MAP2-positive 
cells). Surprisingly, there is a lack of information in the literature regarding the presence of HuC/D- and 
MAP2-positive cells in NS, although some authors point to the presence of βIII-Tubulin-positive cells 
(or Tuj1-positive cells) in NS (Breier et al., 2010; Sun et al., 2011; Suzuki et al., 2004), and, 
particularly, in human NSC (Rieske et al., 2007). Since βIII-Tubulin is a marker of neuronal cells, these 
previous studies corroborate ours. Thus, βIII-Tubulin expression should be confirmed in our cultured 
NS in the future. 
Breier et al. (2010) demonstrated that undifferentiated and differentiated markers are differently 
distributed in the NS. They showed that the nestin-positive cells are located in the periphery of the NS, 
while βIII-Tubulin-positive cells and GFAP-positive cells reside in the center, due to their location in the 
core of neurosphere, where cells do not contact (or have a poor contact) with undifferentiation 
conditions, leading them to differentiate. Thus, it should be interesting to additionally analyse our NS in 
a confocal microscope in order to study the cellular distribution and location of differentiated and 
undifferentiated cells on these floating aggregates. 
The change of culture media from a proliferative inducer into a differentiate one led to an 
alteration of the protein expression profile. Our results show that in differentiation conditions in vitro, 
cells adopt a characteristic astrocyte-like morphology, with large polyhedral cytoplasm and small 
processes. These data are consistent with the work described by Brunet et al. (2004) in which this 
differentiation method was developed. Comprehensively, the expression levels of differentiated cell 
markers increase along differentiation into astrocytes, particularly the astrocytic markers, while those 
of undifferentiated ones decrease. The highest expression levels along differentiation belong to GFAP 
and GLAST markers since these are specific astrocytes markers. Also, their increase is accompanied 
by the reduction of vimentin expression levels. Our results are supported by previous studies in which 
it was found that the low levels of GFAP and GLAST expression in NSC, increase with differentiation 
(Brunet et al., 2004; Sergent-Tanguy et al., 2006). However, like in our work, some cells co-express 
GFAP and vimentin (Li et al., 2011), corresponding to glial cells (Quinlan and Franke, 1983). 
Curiously, the co-expression of vimentin and GFAP was found in all grades of malignancy, such as in 
gliomas (Herpers et al., 1986; Quinlan and Franke, 1983). Sox2 appears to be the marker with the 
third highest expression level in differentiating cells and it is maintained visible in the immunostaining 
assays during all days of differentiation, even when the number of mature astrocytes increases. 
Similarly, although less expressed, also nestin was detected along all the differentiation process. This 
may have happened because some astrocytes express Sox2 (Jinno, 2011) and GFAP-positive cells 
can still co-express a low level of nestin during development and differentiation (Brunet et al., 2004; 
Sergent-Tanguy et al., 2006) because, according to Sergent-Tanguy et al. (2006), differentiated cells 
might retain NSC properties and then express progenitor markers. Interestingly, these same Authors 
argue that due to the late expression of nestin during maturation procedure, nestin-postive cells in 
population tend to aggregate (Sergent-Tanguy et al., 2006). Apparently our results are in accordance 
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with this assumption since we observed that the individualization of the cells occurs in parallel with the 
loss of clusters along the last days of differentiation, also corresponding to a decrease in nestin-
expression.  
Overall, our culture conditions thus favored astrocyte differentiation, once the expression of 
neurons and oligodendrocytes markers are decreasingly observed and inversely correlated with the 
ones of astrocytes along differentiation. Accordingly with Brunet et al. (2004) and Breier et al. (2010), 
the removal of growth factors, particularly the EGF one, prevents the maintenance of the cells as 
undifferentiated, while, the addition of FBS instead leads to differentiation of stem cells into astrocytes 
(Abe et al., 2006; Sakai et al., 1990), therefore increasing the levels of GFAP (Brunet et al., 2004; 
Jinno, 2011). The differentiation into oligodendrocytes is inhibited by the presence of FBS in media, 
due to the presence of the bone morphogenetic protein (BMP) in the serum which belongs to the 
major class of the transforming growth factor β superfamily, known to promote the selective 
differentiation of astrocytes (Mabie et al., 1997; Wang et al., 2012). Moreover, it is described that while 
Sox2 overexpression allows the differentiation of progenitors into astrocytes, it inhibits neurogenesis 
(Bani-Yaghoub et al., 2006). This concept further supports our data, because the high Sox2 
expression along differentiation could have indeed prevented the neuronal differentiation leading to 
the observed low levels of neuronal markers.  
Regarding all of these results, it will be tempting to perform, in the future, the evaluation of the 
markers here used in the characterization of NS and differentiating cells by flow cytometry (GUAVA), 
to confirm the data obtained given its highest specificity.  
As previously mentioned, gliomas are formed by a heterogenous mixture of several glial 
phenotypes, composed simultaneously by immature cell types, poorly differentiated astrocytes and 
mature cells (Park and Rich, 2009; Siebzehnrubl et al., 2011). Similarly, NS and first days 
differentiated cultured NS into astrocytes are also composed by a heterogenic cellular mixture, and as 
so we may talk about some degree of resemblance between glioma cells and differentiating-
astrocytes.   
Several studies have been developed to understand the similarities between glioma cells and 
NSPC, suggesting that the transformation of NSC or NPC first can be in the origin of gliomas. 
According to some recent works, modifications in the normal course in the differentiation of glial NPC 
may lead to the generation of abnormal cells, instead of mature astrocytes (or oligodendrocytes) 
(Sanai et al., 2005). Thus, in the present work, the expression of some tumour-related factors was 
evaluated in primary NS, differentiating-astrocytes and GL261 cells, in order to investigate which 
developmental stage, from NS to differentiating astrocytes, had the highest tumourigenic potential.  
The multidrug resistance phenomenon can be mediated by several ABC transporters (Kondo, 
2006; Sutter et al., 2007), and regarding tumours, it is one of the main causes of treatment failure and 
disease progress. Mrp1, the best studied of the nine members of Mrp family (family of ABC 
transporters), has been detected in gliomas cell lines (Bart et al., 2000; Calatozzolo et al., 2005), as 
well as Mrp3 (with structure similarities to Mrp1 protein), a protein that Kuan et al. (2010) showed to be 
highly expressed in human GBM but not in normal brain cells. Moreover, Mrp1 expression, that 
revealed to be significantly up-regulated in cancer stem-like cells (Jin et al., 2008) and in CD133
+
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human brain glioma stem cells (Bi et al., 2007), can be one of the reasons why tumour cells resist to 
chemotherapeutic drugs, being suggested that chemosensitization of cells with Mrp1 inhibitors might 
increase the efficacy of the usual glioma treatment (Peignan et al., 2011). Intriguingly, undifferentiated 
NPC also show high levels of ABC transporters expression (Islam et al., 2005a; Islam et al., 2005b). 
These observations are consistent with our findings showing higher Mrp1 levels in NS and GL261 
cells. Recently, Jin et al. (2010) by comparing NSC and CSC found that both had high Mrp1 
expression level. While the high levels in NS or in NSPC are necessary to their proliferation (Lin et al., 
2006), in gliomas (particularly in glioma CSC) Mrp1 seem to be related with the resistance to 
multidrugs in the course of therapeutic methodologies (Dean et al., 2005; Salmaggi et al., 2006). In the 
differentiating-astrocytes this expression level begins to be lost with the increase of differentiation and 
consequent reduction of the number of undifferentiated cells, except in the last day of the 
differentiation process, where it occurs a high Mrp1 expression level. However these data were 
noticed by Calatozzolo et al. (2005) even in human normal mature astrocytes.  
Autophagy is a subcellular process that degrades damaged organelles and proteins and 
involves a membranous organelle, the autophagosome (Liu et al., 2011; Rubinsztein et al., 2007). 
Autophagy has been implicated both in development and immunity (Chen et al., 2012; Levine and 
Deretic, 2007), and an abnormality in this autophagic process is related to malignant diseases. 
Therefore, autophagy can be both oncogenic and tumour suppressive, suggesting that the process 
can have different roles at the several stages of tumour development (Macintosh et al., 2012). 
Moreover, autophagy develops an important role in the regulation of self-renewal, differentiation, 
tumourigenic potential and radiosensitization of glioma-initiating cells, indicating that autophagy 
induction can promote the differentiation of these cells and their susceptibility to radiotherapy 
(Palumbo et al., 2012; Teres et al., 2012; Zhuang et al., 2011). Hence, to combat this phenomenon, it 
has been tested drugs that induce autophagy instead of apoptosis in malignant glioma cells (Kanzawa 
et al., 2004). Aoki et al. (2008) showed that LC3B (an autophagic marker) was expressed in vivo and 
in vitro glioma cells. Concerning embryonic development, some evidences support the existence of a 
complex interplay between autophagy and cell proliferation during mammalian neural development 
(Fimia et al., 2007). Moreover, Vazquez et al. (2012) referred that during differentiation, neuroephetilial 
cells undergo efficient remodel of their cytoskeleton and shape in an energy-consuming process, and 
since autophagy is required to recycle cellular components and provide energy, this mechanism could 
fulfill these requirements, supporting differentiation. Although it has been used a different autophagic 
marker, our results are coherent with these observations since the autophagic marker LC3B that we 
used evidenced to increase along differentiation, when cells begin to acquire a more specific fate. 
Surprisingly, the LC3B expression level in the second day of differentiating-astrocytes revealed to be 
increased as compared to glioma cells, probably as a consequence of the higher heterogenic 
population of differentiating cells that compose those phenotypes. In fact, glioma cell population 
evidenced a higher similarity to NS or one day differentiating-astrocytes. Nevertheless, these results 
need to be reassured by further experiments. 
The activity  of many MMP has been detected in the nervous system (Fujioka et al., 2012). 
MMP mediate the degradation of protein components of ECM in a variety of physiological and 
IV. DISCUSSION 
55 
 
pathological tissue remodeling processes, including embryo implantation, tumour invasion, metastasis, 
angiogenesis (Forsyth et al., 1999; Hagemann et al., 2012) and neovascularization (Sun et al., 2012). 
Levels of MMP-2 and MMP-9 are significantly elevated in injured brains (Fujioka et al., 2012). Sun et 
al. (2012) have verified that these two gelatinases are present in glioma specimens from patients and, 
most importantly, they were correlated, with the progression and the prognosis of these malignant 
tumours. Thus, the invasion ability of glioma is associated with the amount of MMP. Particularly, 
Thorns et al. (2003) demonstrated that besides MMP-2 and MMP-9 astrocytomas also exhibited 
immunostaining for, MMP-7, MMP-10 and MMP-11. Our results are somewhat consistent with the 
above described works. In fact, GL261 cells expressed MMP although we were expecting a higher 
level of expression, such as the one found by Hagemann et al. (2012) in GBM-cell lines. More 
commonly,  MMP are abundantly expressed in NSC isolated from the human CNS (Frolichsthal-
Schoeller et al., 1999) and play an important role in embryonic development (Ethell and Ethell, 2007). 
Fujioka et al. (2012) have shown that MMP might promote proliferation, neurite extension, and 
migration of newborn neurons in the developing brain. Wang et al. (2006) also relate MMP-2 and 
MMP-9 expression with neural progenitor cell migration and hypothesized that these gelatinases might 
play a role in providing an optimal niche for neural stem/progenitor cells. In the CNS, MMP-2 can be 
detected in various brain structures including astroglia and some neurons in the cortex, whereas the 
MMP-9 is expressed in the hippocampus, cerebellum, and cortex, predominantly in neurons (Fujioka 
et al., 2012). Such observations are consistent with our work since we found MMP-9 and MMP-2 
expression in NS and in differentiating cells. We suggest that the increased activity of MMP-2, as 
compared to MMP-9, can derive from the increased expression of MMP-2 mainly in astroglia, the 
predominant phenotype of differentiating cells as already mentioned. Regarding MMP-9 expression, 
we have observed that an increased expression is present in NS till the second/third day of 
differentiating-astrocytes, decreasing thereafter. These results are supported by data from Fujioka et 
al. (2012), showing that the increase in the MMP-9 expression coincided with the phenotypes 
composed by NPC and with the increased representation of neuronal cells since MMP-9 expression 
mainly occurs in neurons. The decrease of MMP-9 in the more differentiated astrocytes stages can 
derive from the low percentage of neuronal cells representation. Overall, we believe that MMP should 
not be considered as the most reliable factor to ascertain about the developmental stage most similar 
to glioma, due to the activity variability along differentiation. 
Regarding S100B, this protein is known to be involved in proliferation, differentiation and 
migration/invasion among other aspects. Previous studies have described that S100B is concentrated 
in astrocytes and in other glial cell types, which constitutively may release it (Yang et al., 1995; Zhang 
et al., 2011). S100B expression defines a late developmental stage after which GFAP-expressing cells 
loose NSC potential and ability to form NS and to acquire a mature developmental state (Raponi et al., 
2007). Moreover, it is described that at nanomolar concentrations (as the ones observed in 
neurospheres), S100B exerts neurotrophic properties for normal brain development (Rothermundt et 
al., 2003). However, despite its paracrine/autocrine trophic effects at physiological concentrations, 
higher levels of S100B have shown toxic effects and have been detected in brain tumours (Michetti et 
al., 2012), particularly in astrocytomas (Zhang et al., 2011). Interestingly, such as MMP, S100B protein 
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is considered to promote cell invasion and migration, and to be related with the development of brain 
metastasis (Pang et al., 2012). S100B also contributes to tumourigenesis by inhibiting the function of 
the tumour suppressor protein p53 (Lin et al., 2004) and by regulating cell proliferation and 
differentiation through stimulation of mitogen protein kinases (Arcuri et al., 2005). According to these 
observations, Brozzi et al. (2009) found that S100B stimulates C6 glioma proliferation, also 
participating in normal astrocytes proliferation and activation through interactions with Src kinase. In 
our work we found a high release of S100B by GL261 cells (micromolar concentrations), corroborating 
data of the works previously referred. Such levels of S100B, described to increase cellular proliferation 
(Brozzi et al., 2009; Leclerc et al., 2007), suggest that S100B may contribute to reduce the 
differentiation potential of cells of the astrocytic lineage, then contributing to maintain an invasive 
phenotype.  In contrast to our expectations of an increase in the S100B release along differentiation, 
as the cells loose NSC-potential and acquire a mature state, we only verified high levels in the second 
day of differentiating-cells. Therefore it highly recommendable to validate these results by using an 
alternative method of S100B evaluation, such as the immunoluminometric sandwich assay (ILMA) 
(Ghanem et al., 2001; Steiner et al., 2006).  
The VEGF family is a potent regulator of angiogenesis and vascular permeability that uses 
tyrosine kinase receptors (in particular, VEGFR) to mediate its activities (Takahashi and Shibuya, 
2005). VEGF not only promotes angiogenesis but is also a key factor in proliferation of malignant brain 
tumours (Sjostrom et al., 2011). This growth factor promotes tumourigenesis, via angiogenesis, of 
human glioblastoma stem cells, resulting in its rapid growth. Oka et al. (2007) showed that VEGF 
injection into the mouse brain leads to the massive expansion of vascular-rich GBM.  Additionally, 
VEGFR-2 plays a crucial role in glioblastoma development (Sharma and Saad, 2011), prognosis, and 
response to therapy. Such as lately demonstrated by Sjostrom et al. (2011) the inhibition of VEGFR-2 
by ionizing radiation increase tumour cell death. In astrocytomas, Knizetova et al. (2008) found that 
VEGFR-2 is coexpressed with VEGF, leading to tumourigenesis. 
Our results seem to corroborate these observations since we have found high levels of VEGF 
and VEGFR-2 expression in GL261 cells. VEGF is also highly expressed by embryonic NSPC in 
culture and believed to contribute to developmental processes, including proliferation, differentiation, 
maturation, vascularization and neurogenesis (Kim et al., 2007; Roitbak et al., 2008; Shetty et al., 
2005). In accordance, inhibition of the VEGF signaling reduces migration and induces differentiation 
(Joo et al., 2012; Kaus et al., 2010). These data are consistent with our findings evidencing an 
increase in VEGF and VEGFR-2 expression from NS to the second day of differentiating-cells, i.e. 
until a high number of undifferentiated cells is achieved, and a decrease when cells acquire a more 
differentiated state. This explains the study of Palmer et al. (2000) who showed that although 
expression of VEGF, as well as of its receptors, continues within the adult neurogenic zone, VEGF is 
not expressed in adult brain, out of these areas. Therefore, the reduction of VEGF and VEGFR-2 in 
the last day of differentiation, as in the cited work, may derive from cell-maturation inducing their 
decrease. Interestingly, we have verified a higher expression of VEGFR-2 than of VEGF in NS and 
progenitor phenotypes.  
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These enhanced levels of VEGFR-2 expression can be related to results obtained in our work 
regarding migration. Recent studies indicate that tumour-upregulated VEGF acts as a soluble 
chemotactic factor, by inducing tropism of NSC (mainly to glioma) (Colleoni and Torrente, 2008; Joo et 
al., 2012). Considering our results, the first day of differentiating-cells was the stage evidencing the 
highest VEGFR-2 expression together with the most elevated migratory ability. This suggests that 
cells with higher VEGFR-2 expression are attracted more easily to VEGF than those with lower levels 
of expression. Nevertheless, the migration tendency of NSC towards gliomas, demonstrated by 
several in vivo studies, is mediated not only by VEGF but also by growth factors, cytokines and 
chemokines secreted from malignant glioma (Heese et al., 2005; Koizumi et al., 2011). Thus, although 
we have not obtained a high level of migration when cells were submitted to attraction by GL261-
conditioned media, we believe that they were attracted not only by VEGF but also by other additional 
factors. In both cases, highest migration level was observed in the first day of differentiating-cells. 
These findings can be explained by the work of Ehtesham et al. (2004) suggesting that tumour-tropic 
NSC exhibit an astrocytic precursor phenotype. The lower migratory level exhibited by cells at the last 
day of differentiation somehow reinforces the concept that progenitor cells are the ones retaining the 
ability to travel through mature parenchyma. Thus when the nestin-expression is lost, cells loss the 
migratory ability and that when the nestin-expression disappears, cells lose its migratory ability. In fact, 
Sanai et al. (2005) have shown that in the injured adult brain, nestin-positive cells really migrate to the 
site of injury from the SVZ, indicating that progenitor cells retain the ability to travel through mature 
parenchyma. Thus, cells at the first days of differentiation are those behavioring more similarly as they 
have increased number of astrocytic precursors and high nestin-expression levels. Surprisingly, the 
migratory ability of GL261 cells was lower than what we expected. Indeed, in some previous studies it 
was indicated that malignant gliomas have high migratory capacity (Demuth and Berens, 2004; 
Lefranc et al., 2005; Sanai et al., 2005). However, the absence of migratory characteristics was 
ascertained in the GL261 cell line (Benetti et al., 2000), which might explain our results obtained in this 
cell line. Nevertheless, it is important that these migration studies will be reinforced by the application 
of other methodologies, such as the migration fluorimetric assays (Eccles et al., 2005; Hong et al., 
2008; Hsieh et al., 2011). In addition, we believe that it should be important to quantify the content of 
the conditioned media from glioma cells in terms of VEGF concentration, by using ELISA 
methodology, in order to perform migration assays both in NS and in the first day of differentiating-
cells. Moreover, once it is well known the ability of the glioma cells to release monocyte chemotactic 
protein 1 (MCP-1) (Bottazzi et al., 1983; Kuratsu et al., 1989; Meltzer et al., 1977) and since it has 
been shown that this chemokine, expressed both in vivo and in vitro conditions in brain tumour cells, 
has the ability to chemoatract NPC (Magge et al., 2009), it will be interesting to investigate the 
migration of both NS and differentiating-astrocytes towards this protein. 
In summary, using our in vitro model of neural stem/precursor cells proliferation and 
differentiation, the main concluding remarks of this study are that: a) the methodology used to promote 
differentiation of NS into astrocytes was effective since after seven days in vitro, with the described 
growth media, cells acquired properties of mature astrocytes; b) first and second days of differentiating 
astrocytes evidence the closest similarities to GL261 cells, regarding some tumour-related factors. 
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Together we conclude that these phenotypes show a great potential to be in the origin of gliomas. The 
main results and conclusions obtained in this study are summarized in Fig.IV.1.  
 
 
Fig. IV.1 – Summary of the main results and conclusions from the study. A) Representation of cellular 
markers along differentiation. The gradual increase or decrease of colors (ranging from light to dark, or vice 
versa) for each marker, corresponds, respectively, to an increase or decrease of its expression in neurospheres 
(NS) and in cell days in vitro under differentiation conditions (DIV). Throughout differentiation there is a decrease 
of Sox2- (that stains stem/progenitor cells), nestin- (stem/progenitor cells), vimentin- (progenitor glial cells), and 
NG2- (oligodendroglial progenitors) positive cells, in parallel with an increase in GFAP- (glial fibrillary acidic 
protein, mature/differentiated astrocytes) and GLAST- (glutamate aspartate transporter, differentiating astrocytes) 
positive cells. In addition, there was an increase of HuC/D- (neuronal progenitors) and MAP2- (microtubule-
associated protein 2, mature/differentiated neurons) positive cells until the 3 DIV, followed by a decrease till the 7 
DIV. B) Representation of the tumour-related factors expression in NS, differentiating astrocytes and GL261 
(glioma cell line) cells. The gray arrows represent the level of factor expression; sequentially, three arrows 
indicate the highest expression level), two arrows (the intermediate expression level), and one arrow (the lowest 
expression level). Arrows pointing upwards represent the increase of expression relatively to the previous DIV, 
while arrows pointing down represent the decrease of expression relatively to the previous DIV. The red squares 
symbolize, for each evaluated factor, the value (and the phenotype) most similar to the level of expression in 
GL261 cells. Overall, the phenotypes with major similar factors when compared to GL261 cells, are the 1 and 2 
DIV differentiating astrocytes. MMP, matrix metalloproteinasexs; Mrp1, multidrug resistance-associated protein 1; 
VEGF, vascular endothelial growth factor; VEGFR-2, vascular endothelial growth factor receptor 2.  
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Future perspectives 
 
According to the literature, cells can express more tumour-related factors when involved in the 
tumoural mass; thus, we intend to plate our cells (NS and differentiating astrocytes) in GL261-
conditioned media. This methodology will allow us to observe whether NS and differentiating 
astrocytes in the presence of glioma cells, express higher levels of tumour-related factors, namely the 
parameters evaluated by us in the present work, than in their growth media.  
It would be also interesting, as initially intended, to silence some genes which are thought to be 
more involved in tumourigenesis, such as PTEN and p53 (Zheng et al., 2008), in both NS and 
differentiating cells, thus inducing a malignant transformation of these cells. Then, we aim to evaluate 
which transformed phenotype will be closer to the phenotypr and will acquire the same tumourigenic 
properties of glioma cells. Additionally we also intend to evaluate the expression of CD133-positive 
cells, in order to identify the percentage of tumour-initiating cells on these phenotypes and on glioma 
cells. The CD133 is a neural stem marker, and therefore it will identify the brain tumour stem cells. In 
fact, it has been described that GBM have abundant clusters of CD133-positive cells, which are called 
the glioblastoma stem cells (Christensen et al., 2011; Pfenninger et al., 2007). 
Finally, since in this work we have studied the migratory capability of NS and differentiating-
astrocytes towards glioma cells, we intend to further explore the potential of these cells in glioma 
treatment. Thus, we additionaly aim to develop drug-loaded lipid nanoparticles that will be 
incorporated in these cells, in an attempt to use these systems as a promising tool to efficiently deliver 
drugs into the brain tumours. 
 
In summary, the important issues that need to be explored in the future are the interaction 
between NS, differentiating astrocytes, and tumour cells, to better understand two particular points: (i) 
do these undifferentiating cells enhance or contribute to tumour growth and/or invasion ability? Are 
these cells suitable to deliver therapeutical compounds into gliomas? These are in fact important 
questions that surely deserve to be further exploited. 
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